var title_f25_26_26016="ACLS algorithm stable VT";
var content_f25_26_26016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Stable ventricular tachycardia (monomorphic or polymorphic) algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 564px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2000; 102:I-163.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_26_26016=[""].join("\n");
var outline_f25_26_26016=null;
var title_f25_26_26017="Talar tilt test";
var content_f25_26_26017=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Talar tilt test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The talar tilt test is for integrity of the calcaneofibular ligament. With the ankle in the neutral position, a gentle inversion force is applied to the affected ankle, and the degree of inversion is observed and compared to the uninjured side.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_26_26017=[""].join("\n");
var outline_f25_26_26017=null;
var title_f25_26_26018="Patient information: Skin cancer (non-melanoma) (The Basics)";
var content_f25_26_26018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15500\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/25/4504\">",
"         Nonmelanoma skin cancer",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/46/42722\">",
"         Patient information: Melanoma skin cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/30/18913\">",
"         Patient information: Sunburn (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/60/33729\">",
"         Patient information: Sunburn prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Skin cancer (non-melanoma) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/skin-cancer-non-melanoma-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H544790589\">",
"      <span class=\"h1\">",
"       What is skin cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Skin cancer happens when normal cells in the skin change into abnormal cells. There are two main types of skin cancer: melanoma and non-melanoma. Non-melanoma skin cancer can occur anywhere on the skin, but is often on the head, face, neck, back of the hands, arms, and legs. This is because those body parts are most exposed to the sun&rsquo;s rays.",
"     </p>",
"     <p>",
"      Skin cancer is often caused by sun exposure and sunburn. In fact, the damaging effects of the sun build up over time. The more you are exposed to the sun (or to tanning beds) in your life, the higher your risk of skin cancer.",
"     </p>",
"     <p>",
"      The two most common types of non-melanoma skin cancer are called &ldquo;basal cell carcinoma&rdquo; and &ldquo;squamous cell carcinoma.&rdquo; Most forms of non-melanoma skin cancer can be easily treated because they grow slowly. But if not treated, some non-melanoma skin cancers can become large or spread inside the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544790596\">",
"      <span class=\"h1\">",
"       What are the symptoms of non-melanoma skin cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Skin cancer looks like an abnormal area of skin (",
"      <a class=\"graphic graphic_picture graphicRef62777 \" href=\"UTD.htm?4/25/4504\">",
"       picture 1",
"      </a>",
"      ) and can be:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pink",
"       </li>",
"       <li>",
"        Red and swollen",
"       </li>",
"       <li>",
"        Peeling",
"       </li>",
"       <li>",
"        Bleeding or look like an open sore",
"       </li>",
"       <li>",
"        Thick or crusty",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other skin changes due to sun damage can also occur. Some people, especially those with fair skin, can get scaly, rough, or bumpy spots called &ldquo;actinic keratoses.&rdquo; Actinic keratoses are often found on the face, ears, arms, or scalp. They can sometimes turn into skin cancer. Doctors often treat actinic keratoses to decrease the chance that this will happen.",
"      <br/>",
"     </p>",
"     <p>",
"      Skin changes can also be caused by conditions that are not cancer. But you should show your doctor or nurse any skin changes you think might be abnormal.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544790603\">",
"      <span class=\"h1\">",
"       Is there a test for skin cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will do an exam and check the skin all over your body. If he or she suspects you have skin cancer, you will have a follow-up test called a biopsy. During a biopsy, a doctor will take a small sample of the abnormal area or remove the whole abnormal area. Then another doctor will look at the skin cells under a microscope to check for cancer.",
"     </p>",
"     <p>",
"      If your doctor suspects that your skin cancer has spread inside your body, you will have other follow-up tests. These can include a biopsy from tissue inside your body, or imaging tests. Imaging tests create pictures of the inside of the body and can show abnormal growths.",
"     </p>",
"     <p>",
"      The right treatment for you will depend a lot on the type of skin cancer you have, and its size and location. It will also depend on your age and other health problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544790610\">",
"      <span class=\"h1\">",
"       How is non-melanoma skin cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with non-melanoma skin cancer have one or more of the following treatments:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Surgery",
"        </strong>",
"        &mdash; Skin cancer is usually treated with surgery to remove or destroy the cancer. Doctors can do different types of surgery to treat skin cancer.",
"       </li>",
"       <li>",
"        <strong>",
"         Radiation therapy",
"        </strong>",
"        &mdash; Radiation kills cancer cells.",
"        <strong>",
"        </strong>",
"       </li>",
"       <li>",
"        <strong>",
"         Skin creams",
"        </strong>",
"        &mdash; Your doctor might prescribe a strong cream for you to put on your skin cancer. The medicines in these creams can kill cancer cells.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544790617\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, you will need to be checked every so often to see if the skin cancer comes back or if new skin cancer appears. Your doctor will do an exam and check your skin all over. Most doctors also recommend that you keep checking your skin to look for any new changes. Show your doctor or nurse any skin changes you find.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544790624\">",
"      <span class=\"h1\">",
"       What happens if the cancer comes back or if new skin cancer appears?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the cancer comes back, or if you develop new skin cancer, you might need to have surgery or radiation therapy, or use a prescription skin cream.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544790631\">",
"      <span class=\"h1\">",
"       Can skin cancer be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can help prevent skin cancer by protecting your skin from the sun&rsquo;s rays. To reduce the chance of getting skin cancer, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stay out of the sun in the middle of the day (from 10 a.m. to 4 p.m.)",
"       </li>",
"       <li>",
"        Wear sunscreen and reapply it often",
"       </li>",
"       <li>",
"        Wear a wide-brimmed hat, long-sleeved shirt, or long pants",
"       </li>",
"       <li>",
"        Not use tanning beds",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544790638\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is important to follow all your doctors&rsquo; instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544790645\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/46/42722?source=see_link\">",
"       Patient information: Melanoma skin cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=see_link\">",
"       Patient information: Sunburn prevention (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/30/18913?source=see_link\">",
"       Patient information: Sunburn (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?25/26/26018?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15500 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_26_26018=[""].join("\n");
var outline_f25_26_26018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790589\">",
"      What is skin cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790596\">",
"      What are the symptoms of non-melanoma skin cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790603\">",
"      Is there a test for skin cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790610\">",
"      How is non-melanoma skin cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790617\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790624\">",
"      What happens if the cancer comes back or if new skin cancer appears?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790631\">",
"      Can skin cancer be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790638\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790645\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15500\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/25/4504\">",
"      Nonmelanoma skin cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/46/42722?source=related_link\">",
"      Patient information: Melanoma skin cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/30/18913?source=related_link\">",
"      Patient information: Sunburn (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=related_link\">",
"      Patient information: Sunburn prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_26_26019="Ultraound image of Doppler flow in abnormal axillary lymph node";
var content_f25_26_26019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound image of Doppler flow in abnormal axillary lymph node",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound image of abnormal lymph node. This shows Doppler blood flow within the node.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_26_26019=[""].join("\n");
var outline_f25_26_26019=null;
var title_f25_26_26020="Panitumumab: Patient drug information";
var content_f25_26_26020=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Panitumumab: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/48/6918?source=see_link\">",
"     see \"Panitumumab: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3343189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vectibix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6826223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vectibix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700526",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug can cause bad skin side effects. Talk to your doctor about any skin changes you may have.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700525",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some patients have very bad side effects during the infusion. Tell your doctor if you have any bad effects during the infusion.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2693942",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat colorectal cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to panitumumab or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697725",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust during care and for 6 months after care ends.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever, chills, itching, hives, chest pain or pressure, or shortness of breath when drug is given. Other drugs may be given to avoid these.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698965",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Infusion reaction.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11820 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-EC2EE36D8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_26_26020=[""].join("\n");
var outline_f25_26_26020=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343189\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6826223\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026202\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026204\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026203\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026208\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026209\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026211\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026206\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026213\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/48/6918?source=related_link\">",
"      Panitumumab: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_26_26021="Losartan: Patient drug information";
var content_f25_26_26021=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Losartan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     see \"Losartan: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/19/40247?source=see_link\">",
"     see \"Losartan: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cozaar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F190225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Losartan;",
"     </li>",
"     <li>",
"      CO Losartan;",
"     </li>",
"     <li>",
"      Cozaar&reg;;",
"     </li>",
"     <li>",
"      Mylan-Losartan;",
"     </li>",
"     <li>",
"      PMS-Losartan;",
"     </li>",
"     <li>",
"      Teva-Losartan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691575",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to protect kidney function in diabetic patients who have protein loss.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702413",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to losartan or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703720",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a block in the kidneys' arteries.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High potassium level. Signs include feeling weak, lightheaded, dizzy, feel like passing out, or have numbness or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699474",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) in a refrigerator. Throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10820 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-122.72.80.101-1C61674EA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_26_26021=[""].join("\n");
var outline_f25_26_26021=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190224\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190225\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019211\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019213\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019212\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019217\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019218\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019220\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019215\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019216\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019221\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019222\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=related_link\">",
"      Losartan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/19/40247?source=related_link\">",
"      Losartan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_26_26022="Saxagliptin: Drug information";
var content_f25_26_26022=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Saxagliptin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/10/8357?source=see_link\">",
"    see \"Saxagliptin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16339638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Investigating Unpublished Reports of Pancreatic Toxicity With Incretin Mimetic Drugs",
"     </span>",
"     <span class=\"collapsible-date\">",
"      March 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) is evaluating unpublished new findings that suggest an increased risk of pancreatitis and pancreatic duct metaplasia in patients with type 2 diabetes treated with incretin mimetics. These findings are based on pancreatic tissue samples taken from patients who died from unspecified causes. The FDA has requested these samples, as well as information on the methodology used to collect them, and will communicate its final conclusions and recommendations. Healthcare providers should continue to prescribe incretin mimetics according to the drug label recommendations and patients receiving incretin mimetics are advised to continue therapy as directed and to discuss any concerns with their healthcare provider.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at the following website:",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm343187.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm343187.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7997762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Onglyza&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9608124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Onglyza&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8008270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Dipeptidyl Peptidase IV (DPP-IV) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8008346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Type 2 diabetes:",
"     </b>",
"     Oral: 2.5-5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Concomitant use with strong CYP3A4/5 inhibitors:",
"     </i>",
"     2.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Concomitant use with insulin or insulin secretagogues:",
"     </i>",
"     Reduced dose of insulin or insulin secretagogues (eg, sulfonylureas) may be needed",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8008347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8008348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Renal function may be estimated using the Cockcroft-Gault formula or the MDRD formula for dosage adjustment purposes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;50 mL/minute: 2.5 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     ESRD requiring hemodialysis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     2.5 mg once daily; administer postdialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Peritoneal dialysis: Not studied.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8008349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Mild-to-severe impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Mild impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Moderate-to-severe impairment: Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8008385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onglyza&trade;: 2.5 mg, 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8008268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F13376319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM280356.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM280356.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8008352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals. Swallow whole; do not split or cut tablets.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8008272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise as monotherapy or in combination therapy with other antidiabetic agents to improve glycemic control",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8008266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Saxagliptin may be confused with sitaGLIPtin, SUMAtriptan",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8008285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Frequencies and adverse reactions reported with monotherapy unless otherwise noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (&le;4%; incidence increased in conjunction with thiazolidinediones: &le;8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypoglycemia (&le;6%; incidence increased in conjunction with insulin secretagogues: &le;15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain (2%), gastroenteritis (2%), vomiting (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Lymphopenia (&le;2%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Sinusitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Hypersensitivity reactions (2%; including urticaria and facial edema)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Angioedema, anaphylaxis, creatinine increased, creatine phosphokinase increased, exfoliative skin reactions, idiopathic thrombocytopenic purpura, pancreatitis (acute), rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8008277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to saxagliptin or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Diabetic ketoacidosis, diabetic coma/precoma, type 1 diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8008278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Rare hypersensitivity reactions, including anaphylaxis, angioedema, and exfoliative dermatologic reactions have been reported; discontinue if signs/symptoms of severe hypersensitivity reaction occur. Events have generally been noted within the first 3 months of therapy, and may occur with the initial dose.  Use with caution if patient has experienced angioedema with other DPP-IV inhibitor use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pancreatitis: Cases of acute pancreatitis have been reported with use. Monitor for signs/symptoms of pancreatitis; discontinue use immediately if pancreatitis is suspected and initiate appropriate management. Use with caution in patients with a history of pancreatitis as it is not known if this population is at greater risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Heart failure: Clinical trials included only a limited number of patients with heart failure (HF). No specific recommendations regarding this population are provided in the U.S. manufacturer labeling (Canadian labeling recommends against use in this population).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with moderate-to-severe renal dysfunction and end-stage renal disease (ESRD) requiring hemodialysis; dosing adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; High potential for interactions: Use with caution in patients taking strong CYP3A4/5 inhibitors (eg, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin; also see Drug Interactions); dosage adjustment of saxagliptin is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Insulin: Concomitant use of insulin may increase the risk of hypoglycemia. Monitor blood glucose closely; dosage reduction of insulin may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Insulin secretagogues: Use caution when used in conjunction with insulin secretagogues (eg, sulfonylureas); risk of hypoglycemia is increased. Monitor blood glucose closely; dosage adjustments of the insulin secretagogue may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage forms specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Lactose: Contains lactose; Canadian labeling recommends avoiding use in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption syndromes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7998852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: DPP-IV Inhibitors may enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers: May decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Saxagliptin. Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8008273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8008274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. However, there are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8008276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16571115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if saxagliptin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering saxagliptin to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8008351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals. Individualized medical nutrition therapy (MNT) is an integral part of therapy (ADA, 2013).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Onglyza Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (30): $295.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (90): $885.37",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8008354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma glucose, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     , renal function",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F8008295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Onglyza (AR, AT, AU, BE, BR, CH, CL, CN, CO, CZ, DE, DK, EE, FR, GB, HK, HN, ID, IE, IL, KP, MY, NL, NO, NZ, PH, PL, PT, RU, SE, SG, TH, TR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8008293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Saxagliptin inhibits dipeptidyl peptidase IV (DPP-IV) enzyme resulting in prolonged active incretin levels. Incretin hormones (eg, glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]) regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and decreasing glucagon secretion from pancreatic alpha cells. Decreased glucagon secretion results in decreased hepatic glucose production. Under normal physiologic circumstances, incretin hormones are released by the intestine throughout the day and levels are increased in response to a meal; incretin hormones are rapidly inactivated by the DPP-IV enzyme.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8008296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Negligible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP3A4/5 to 5-hydroxy saxagliptin (active; ~50% potency of the parent compound)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Saxagliptin: 2.5 hours; 5-hydroxy saxagliptin: 3.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Saxagliptin: 2 hours; 5-hydroxy saxagliptin: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (75%, 24% of the total dose as saxagliptin, 36% of the total dose as 5-hydroxy saxagliptin); feces (22%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Allen E, Hollander P, Li J, et al, &ldquo;Saxagliptin Added to a Thiazolidinedione Improves Glycaemic Control in Patients with Inadequately Controlled Type 2 Diabetes,&rdquo;",
"      <i>",
"       Diabetologia",
"      </i>",
"      , 2008, 51(Suppl 1):342-3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, \"Standards of Medical Care in Diabetes--2013,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2013, 36(Suppl 1):11-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/26/26022/abstract-text/23264422/pubmed\" id=\"23264422\" target=\"_blank\">",
"        23264422",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/26/26022/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 20078, 32(suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chacra AR, Tan GH, Apanovitch A, et al, &ldquo;Saxagliptin Added to a Submaximal Dose of Sulphonylurea Improves Glycaemic Control Compared With Uptitration of Sulphonylurea in Patients With Type 2 Diabetes: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Int J Clin Pract",
"      </i>",
"      , 2009, 63(9):1395-406.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/26/26022/abstract-text/19614786/pubmed\" id=\"19614786\" target=\"_blank\">",
"        19614786",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeFronzo RA, Hissa MN, Garber AJ, et al, &ldquo;The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes on Metformin Alone,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(9):1649-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/26/26022/abstract-text/19478198/pubmed\" id=\"19478198\" target=\"_blank\">",
"        19478198",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2011, 17(Suppl 2):1-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/26/26022/abstract-text/21474420/pubmed\" id=\"21474420\" target=\"_blank\">",
"        21474420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al, &ldquo;Saxagliptin Given in Combination With Metformin as Initial Therapy Improves Glycaemic Control in Patients With Type 2 Diabetes compared With Either Monotherapy: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Diabetes Obesity Metab",
"      </i>",
"      , 2009, 11(6):611-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/26/26022/abstract-text/19515181/pubmed\" id=\"19515181\" target=\"_blank\">",
"        19515181",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/26/26022/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nathan DM, Buse, JB, Davidson MB, et al, &ldquo;Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(1):193-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/26/26022/abstract-text/18945920/pubmed\" id=\"18945920\" target=\"_blank\">",
"        18945920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/26/26022/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/26/26022/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenstock J, Aguilar-Salinas CA, Klein E, et al, &ldquo;Once-Daily Saxagliptin Monotherapy Improves Glycemic Control in Drug-Na&iuml;ve Patients With Type 2 Diabetes,&rdquo; Presented at 68th Scientific Sessions of the American Diabetes Association; June 6-10, 2008; San Francisco, CA. Abstract 517-P.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9534 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-22DD962998-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_26_26022=[""].join("\n");
var outline_f25_26_26022=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16339638\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7997762\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9608124\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008270\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008346\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008347\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008348\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008349\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008385\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008268\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13376319\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008352\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008272\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008266\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008285\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008277\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008278\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837684\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998852\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008273\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008274\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008276\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16571115\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008351\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322600\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008354\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008295\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962012\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008293\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008296\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9534\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9534|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/10/8357?source=related_link\">",
"      Saxagliptin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_26_26023="Trichostrongylosis eggs";
var content_f25_26_26023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Trichostrongylosis eggs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 546px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A, B) Eggs of",
"    <em>",
"     Trichostrongylus",
"    </em>",
"    spp in an unstained wet mount of stool.",
"    <br>",
"     (C, D) Eggs of",
"     <em>",
"      Trichostrongylus",
"     </em>",
"     spp in an unstained wet mount of stool. Images courtesy of the Indiana State Department of Health.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Trichostrongylosis. Available at:",
"      <a href=\"file://www.dpd.cdc.gov/dpdx/html/Frames/S-Z/Trichostrongylosis/body_Trichostrongylosis_mic1.htm\" target=\"_blank\">",
"       file://www.dpd.cdc.gov/dpdx/html/Frames/S-Z/Trichostrongylosis/body_Trichostrongylosis_mic1.htm",
"      </a>",
"      .",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_26_26023=[""].join("\n");
var outline_f25_26_26023=null;
var title_f25_26_26024="Injectable soft tissue fillers: Permanent agents";
var content_f25_26_26024=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Injectable soft tissue fillers: Permanent agents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/26/26024/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/26/26024/contributors\">",
"     Alastair Carruthers, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/26/26024/contributors\">",
"     Jean Carruthers, MD, FRCSC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/26/26024/contributors\">",
"     Shannon Humphrey, MD, FRCPC, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/26/26024/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/26/26024/contributors\">",
"     Jeffrey S Dover, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/26/26024/contributors\">",
"     Charles E Butler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/26/26024/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/26/26024/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/26/26024/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H879724\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue fillers are used alone or in combination with other aesthetic procedures to correct wrinkles and to restore tissue volume lost due to aging, lipoatrophy, or other causes. In contrast to resorbable fillers such as hyaluronic acid, fillers that contain polymethylmethacrylate microspheres, silicone, or hydrogel polymers persist indefinitely in tissue. Cautious and conservative use of permanent fillers is essential, as improper injection techniques can lead to long-lasting adverse effects.",
"   </p>",
"   <p>",
"    The efficacy, use, and adverse effects of permanent soft tissue filling agents will be reviewed here. Information on resorbable soft tissue fillers and an overview of the clinical use and complications of soft tissue fillers are available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=see_link\">",
"     \"Injectable soft tissue fillers: Semipermanent agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27049?source=see_link\">",
"     \"Injectable soft tissue fillers: Overview of clinical use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3502728\">",
"    <span class=\"h1\">",
"     PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients can achieve cosmetically pleasing results with semipermanent fillers, and the decision to utilize a permanent filling agent should be considered carefully. In the event that a hyaluronic acid gel (a commonly used semipermanent filling agent) is placed incorrectly in tissue, the adverse cosmetic result can be rapidly corrected through the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"     hyaluronidase",
"    </a>",
"    or can be left to spontaneously resolve over the course of several months as the filler is degraded. In contrast, unfavorable cosmetic results following misplacement of permanent fillers may require surgical intervention and may be difficult or impossible reverse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=see_link&amp;anchor=H1117242#H1117242\">",
"     \"Injectable soft tissue fillers: Semipermanent agents\", section on 'Reversal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additionally, use of a filling agent with a limited duration of effect provides the clinician with the flexibility to respond to changes in patient preferences and allows the clinician to adjust the placement of fillers in concordance with the cutaneous and structural changes that occur with age over time. Thus, patients who desire treatment with permanent filling agents must be screened carefully. Patients who are unsure of their desired outcomes, who have a history of unsubstantiated poor satisfaction with cosmetic treatments, or who are new to the use of soft tissue fillers are poor candidates for treatment with permanent agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15763905\">",
"    <span class=\"h1\">",
"     POLYMETHYLMETHACRYLATE MICROSPHERES",
"    </span>",
"    &nbsp;&mdash;&nbsp;ArteFill",
"    <sup>",
"     &reg;",
"    </sup>",
"    (Suneva Medical Inc., San Diego, CA) is a nonbiodegradable injectable filling agent composed of 30 to 50 &micro;m polymethylmethacrylate (PMMA) microspheres suspended in a water-based gel containing 3.5% bovine collagen and 0.3%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    . Previous formulations of PMMA microspheres were marketed under the names Arteplast",
"    <sup>",
"     &reg;",
"    </sup>",
"    and Artecoll",
"    <sup>",
"     &reg;",
"    </sup>",
"    . Modifications in microsphere size and product purification methods have improved the biocompatibility of ArteFill",
"    <sup>",
"     &reg;",
"    </sup>",
"    compared with its precursors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ArteFill",
"    <sup>",
"     &reg;",
"    </sup>",
"    is the only injectable permanent filling agent approved by the US Food and Drug Administration (US FDA), and this approval is limited to its use for nasolabial folds. However, ArteFill",
"    <sup>",
"     &reg;",
"    </sup>",
"    has been used for a variety of other indications, including additional facial wrinkles, contour defects on the face and neck, and acne scars [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H873135\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;After implantation, the bovine collagen component of ArteFill",
"    <sup>",
"     &reg;",
"    </sup>",
"    dissipates over the course of one to three months, leaving behind the nonbiodegradable PMMA microspheres [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/4\">",
"     4",
"    </a>",
"    ]. The microspheres stimulate a local inflammatory reaction that is followed by the deposition of granulation tissue during the first few weeks after implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/1\">",
"     1",
"    </a>",
"    ]. The connective tissue subsequently matures, and by three months after injection, PMMA microspheres are surrounded by newly formed collagen. The presence of new collagen accounts for the observed volume-filling effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H873242\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of PMMA microspheres for facial wrinkles was evaluated in a randomized trial of 251 patients treated with either a PMMA filler (Artecoll",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) or a collagen filler (Zyderm",
"    <sup>",
"     &reg;",
"    </sup>",
"    II or Zyplast",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/4\">",
"     4",
"    </a>",
"    ]. A total of 1334 glabellar frown lines, nasolabial folds, radial upper lip lines, and marionette lines were treated in up to two treatment sessions over the course of one month. Six months after treatment, photographic assessment by masked observers revealed that PMMA was superior to collagen fillers for the treatment of nasolabial folds. Although the masked observers did not detect a statistically significant difference in improvement for the other treated sites at this time point, an extended phase of the study for patients treated with PMMA found statistically significant improvement in wrinkle severity scores compared to baseline values for all four sites at 12 months. In addition, long term follow-up studies of recipients of PMMA fillers indicate that beneficial effects can persist for at least four to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H873142\">",
"    <span class=\"h2\">",
"     Use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to other soft tissue fillers that contain bovine collagen, patients must be skin-tested for hypersensitivity reactions to bovine collagen prior to injection. Skin tests are performed with intradermal injection of 0.1 mL of collagen on the ventral forearm four weeks prior to treatment. Patients with positive skin tests should not be treated. PMMA injections are also contraindicated for patients with known allergies to any of the product ingredients or a history of keloid or hypertrophic scar formation.",
"   </p>",
"   <p>",
"    Individuals with well-defined lines and furrows and minimal excess skin are good candidates for treatment with PMMA [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/3\">",
"     3",
"    </a>",
"    ]. Injections are",
"    <strong>",
"     not",
"    </strong>",
"    recommended for areas of thin skin, such as the lower eyelid and neck, or for patients with generally thin, loose skin, as the implant may remain palpable or visible [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, PMMA should",
"    <strong>",
"     not",
"    </strong>",
"    be used in the lips due to an increased risk for lumpiness or beading after injection.",
"   </p>",
"   <p>",
"    ArteFill",
"    <sup>",
"     &reg;",
"    </sup>",
"    is supplied in prefilled syringes, and a 26-gauge needle is typically used for injection. The product should be implanted in the deep reticular dermis and overcorrection of defects should be avoided. A series of conservative injections is often required to achieve optimal results.",
"   </p>",
"   <p>",
"    Touch-up injections can be performed one to three months after the initial treatment. Because new collagen synthesis contributes to the effect of ArteFill",
"    <sup>",
"     &reg;",
"    </sup>",
"    , optimal results occur after approximately 3 to 12 months. Additional improvement more than one year after treatment may also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H873149\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential complications of PMMA include nodules due to superficial placement, persistent redness or telangiectasias, hypertrophic scarring, or the delayed appearance of granulomas. Granulomas occurred in approximately 2.5 percent of patients treated with Arteplast",
"    <sup>",
"     &reg;",
"    </sup>",
"    and 0.02 percent of patients treated with Artecoll",
"    <sup>",
"     &reg;",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/2,5,8\">",
"     2,5,8",
"    </a>",
"    ]. The risk for granuloma formation after treatment with ArteFill",
"    <sup>",
"     &reg;",
"    </sup>",
"    appears to be lower than for Artecoll",
"    <sup>",
"     &reg;",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utilization of proper injection technique may reduce the risk for adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/3\">",
"     3",
"    </a>",
"    ]. When they occur, granulomas can be treated with intralesional corticosteroid injection. Nodules and hypertrophic scarring also can respond to intralesional corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/3,9\">",
"     3,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15763919\">",
"    <span class=\"h1\">",
"     HYDROGEL POLYMERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrogel polymer fillers are synthetic, nonbiodegradable, hydrophilic gels with a high degree of elasticity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H873899\">",
"    <span class=\"h2\">",
"     Polyacrylamide hydrogel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available throughout Europe, Australia, Asia, Canada and Mexico, Aquamid",
"    <sup>",
"     &reg;",
"    </sup>",
"    and Aquamid",
"    <sup>",
"     &reg;",
"    </sup>",
"    Reconstruction (Contura, Copenhagen, Denmark) are nonbiodegradable filling agents comprised of 2.5 percent cross-linked polyacrylamide and 97.5 percent water [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/10\">",
"     10",
"    </a>",
"    ]. Aquamid",
"    <sup>",
"     &reg;",
"    </sup>",
"    Reconstruction is slightly more viscous than Aquamid",
"    <sup>",
"     &reg;",
"    </sup>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H874204\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyacrylamide hydrogel augments soft tissue exclusively through a direct, volume-filling effect. The hydrogel becomes an integrated part of the patient&rsquo;s soft tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H874220\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyacrylamide hydrogel is effective for soft tissue filling [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. In a 12-month randomized trial of 315 patients treated for nasolabial folds, the efficacy of Aquamid",
"    <sup>",
"     &reg;",
"    </sup>",
"    was similar to a hyaluronic acid filler (Restylane",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/16\">",
"     16",
"    </a>",
"    ]. Side effects were mostly mild and transient and similar for both treatment groups. Of note, one serious treatment-related infection occurred among the patients treated with Aquamid",
"    <sup>",
"     &reg;",
"    </sup>",
"    . The infection resolved after antibiotic therapy and surgical removal of the product.",
"   </p>",
"   <p>",
"    Polyacrylamide hydrogel was also effective for facial soft tissue augmentation in an uncontrolled study of 251 patients with various facial contour or soft tissue defects. After 12 months, 93 percent of the 228 patients who were available for follow-up exhibited good or very good responses to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/12\">",
"     12",
"    </a>",
"    ]. The benefits of treatment were long-lasting; similar rates of response were observed in a subset of patients five years after their last treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H874440\">",
"    <span class=\"h3\">",
"     Use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aquamid",
"    <sup>",
"     &reg;",
"    </sup>",
"    and Aquamid",
"    <sup>",
"     &reg;",
"    </sup>",
"    Reconstruction are used for the treatment of deep wrinkles and folds and for the correction of facial contours. The products are supplied in prefilled syringes as Aquamid",
"    <sup>",
"     &reg;",
"    </sup>",
"    and Aquamid",
"    <sup>",
"     &reg;",
"    </sup>",
"    Reconstruction. The more viscous Aquamid",
"    <sup>",
"     &reg;",
"    </sup>",
"    Reconstruction is best suited for injections where a large volume of product is required, such as in the treatment of lipoatrophy. Aquamid",
"    <sup>",
"     &reg;",
"    </sup>",
"    is injected with a 27-gauge needle, and a 25 or 27-gauge needle is typically utilized for injection of Aquamid",
"    <sup>",
"     &reg;",
"    </sup>",
"    Reconstruction.",
"   </p>",
"   <p>",
"    Both products should be placed into the subcutaneous fat and overcorrection should be avoided (",
"    <a class=\"graphic graphic_figure graphicRef54021 \" href=\"UTD.htm?23/19/23858\">",
"     figure 1",
"    </a>",
"    ). Polyacrylamide hydrogels should not be used intradermally, and therefore, are not appropriate for the correction of fine wrinkles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H874302\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyacrylamide hydrogel appears to be well tolerated; side effects are generally temporary and transient, including swelling, pain, redness, hematoma, or pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Other potential side effects include nodule formation, local induration, skin discoloration, and infections [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Delayed granulomatous reactions, ulceration, bone erosion, and migration of polyacrylamide hydrogel in tissue have been reported in a few patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/19-23\">",
"     19-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8872500\">",
"    <span class=\"h2\">",
"     Polyalkylimide hydrogel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bio-Alcamid&trade; (Polymekon, Milan, Italy) is another nonbiodegradable hydrogel. It consists of 96 percent water and 4 percent synthetic reticulate polymer (polyalkylimide). Bio-Alcamid&trade; is not available for use in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H882078\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once implanted, polyalkylimide hydrogel becomes encapsulated by a very thin rim of collagen, isolating it from the host tissues. Similar to polyacrylamide hydrogel, the product&rsquo;s efficacy results from a direct volume-filling effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H882085\">",
"    <span class=\"h3\">",
"     Efficacy and use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyalkylimide hydrogel has been studied most extensively for HIV-associated lipoatrophy and has been effective for this indication in a small randomized trial and case series [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/24-30\">",
"     24-30",
"    </a>",
"    ]. The product has also been used for other indications, including lip augmentation and the cosmetic improvement soft-tissue and bony contour defects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/26,31,32\">",
"     26,31,32",
"    </a>",
"    ]. Like polyacrylamide, injections should be placed into the subcutaneous fat (",
"    <a class=\"graphic graphic_figure graphicRef54021 \" href=\"UTD.htm?23/19/23858\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H882092\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common adverse effects of injection include mild and transient swelling, pain, bruising, and erythema [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/30\">",
"     30",
"    </a>",
"    ]. There have also been reports of infections developing months to years after implantation, delayed inflammatory reactions, and migration of the product in tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/10,33-40\">",
"     10,33-40",
"    </a>",
"    ]. Granulomas have occurred in at least two patients treated with this agent for lip augmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6313044\">",
"    <span class=\"h1\">",
"     LIQUID INJECTABLE SILICONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of liquid injectable silicone (purified polydimethylsiloxane) for soft-tissue augmentation is controversial due to concern over the potential for long term complications. Liquid injectable silicone should be utilized only by experienced and expert injectors in carefully selected patients. In the United States, liquid silicone is US FDA approved only for intraocular use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6313086\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of liquid injectable silicone as a soft tissue filler results from a combination of a direct volume-filling effect of the injected material and the formation of new collagen around individual silicone microdroplets in tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6313093\">",
"    <span class=\"h2\">",
"     Efficacy and safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have evaluated the use of liquid injectable silicone for cosmetic soft tissue augmentation. In a retrospective study of 916 patients treated by a single practitioner with liquid injectable silicone (1000-centistoke purified polydimethylsiloxane) for rhytides, acne scars, lip augmentation, or facial contour defects, treatment appeared to be effective and safe [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/43\">",
"     43",
"    </a>",
"    ]. Adverse effects included signs of overcorrection in 11 patients (1 percent) and hyperpigmentation in one patient. No granulomatous or other persistent inflammatory reactions were noted.",
"   </p>",
"   <p>",
"    A pilot study in which 77 patients were injected with silicone to correct HIV-associated lipoatrophy also found that treatment was well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/44\">",
"     44",
"    </a>",
"    ]. Adverse events were limited to mild and transient pain, edema, erythema, and ecchymoses. In a separate series of 179 patients treated with liquid injectable silicone for lip augmentation who were followed for three to seven years, 85 percent of patients rated their results as good or excellent, and complications were limited to burning or local hematoma in 6 percent of patients, and small nodules attributed to improper placement of silicone in 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/45\">",
"     45",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Although the risk for serious adverse effects appears to be less than 1 percent when purified, medical grade silicone is used with proper injection techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/42-51\">",
"     42-51",
"    </a>",
"    ], reports of granulomas, disfiguring nodules, lymphedema, and migration of liquid silicone after injection have led to lasting concern over the use of this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/48,52-61\">",
"     48,52-61",
"    </a>",
"    ]. Many complications associated with silicone injection have been the result of improper use, large volume injections, or injection of industrial-grade or adulterated products [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/42,62,63\">",
"     42,62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Granulomas may occur weeks to decades after injection and can be severely disfiguring and debilitating [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/48\">",
"     48",
"    </a>",
"    ]. Treatments have included intralesional corticosteroids, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/42,64-67\">",
"     42,64-67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6313100\">",
"    <span class=\"h2\">",
"     Use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only pure, medical grade silicone should be used for soft tissue augmentation. In the United States, there are two commercially available products: Silikon&trade; 1000 (Alcon Pharmaceuticals, Fort Worth, TX), and its more viscous counterpart, Adatosil&trade; 5000 (Bausch &amp; Lomb Surgical, San Dimas, CA). Due to its less viscous nature, Silikon&trade; 1000 is more suitable for cosmetic soft tissue injection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The microdroplet serial puncture technique, defined as the injection of 0.01 mL or less at 2 to 10 mm intervals subdermally with a small diameter (eg, 27 to 30-gauge) needle, should be employed during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/42,68\">",
"     42,68",
"    </a>",
"    ]. In most cases, no more than 0.5 to 1 mL of silicone should be injected per treatment session, and additional treatments should be separated by no less than one month [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/42\">",
"     42",
"    </a>",
"    ]. Undercorrection is the goal of treatment, as further improvement occurs as new collagen forms around silicone microdroplets. Optimal collagen formation is attained by approximately 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H875327\">",
"    <span class=\"h1\">",
"     AUTOLOGOUS FAT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous fat transfer has been used for the correction of a variety of contour defects involving the face or body [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/69-75\">",
"     69-75",
"    </a>",
"    ]. The main advantage of autologous fat in comparison to other soft tissue fillers is the lack of risk for hypersensitivity or foreign body reactions.",
"   </p>",
"   <p>",
"    Objective data on the longevity of transplanted fat is limited, and the retention of fat has been estimated to range from 20 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/76-79\">",
"     76-79",
"    </a>",
"    ]. A variety of factors, including the harvesting technique, type of fat implanted, treatment site, injection technique, and experience of the injector can influence the efficacy of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/80-85\">",
"     80-85",
"    </a>",
"    ]. The advent of new harvesting and processing techniques, such as the addition of platelet-rich plasma or adipose-derived stem cells to transplanted fat, may lead to improved viability [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/80-84,86\">",
"     80-84,86",
"    </a>",
"    ]. Additional studies are necessary to explore the in vivo efficacy of these interventions.",
"   </p>",
"   <p>",
"    Although the risk for hypersensitivity reactions is negligible, fat transfer procedures can be complicated by morbidity in the donor site, prolonged edema, infections, contour irregularities, and necrosis or calcification of the injected fat [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/87\">",
"     87",
"    </a>",
"    ]. Fat emboli leading to stroke and vision loss have also been reported in association with this autologous fat transfer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26024/abstract/88-98\">",
"     88-98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H881865\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Injectable filling agents are useful for the replacement volume lost from soft tissue due to a variety of factors. Permanent soft tissue fillers persist indefinitely in tissues. The potential adverse effects of permanent filling agents must be considered carefully prior to use. (See",
"      <a class=\"local\" href=\"#H879724\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ArteFill",
"      <sup>",
"       &reg;",
"      </sup>",
"      , a product that contains polymethylmethacrylate microspheres and bovine collagen, is injected into the deep reticular dermis and fills soft tissue through the stimulation of new collagen formation. Due to the bovine collagen component, patients must be skin-tested prior to use. Treatment of the lips and areas of thin skin should be avoided. (See",
"      <a class=\"local\" href=\"#H15763905\">",
"       'Polymethylmethacrylate microspheres'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hydrogel polymers, including polyacrylamide and polyalkylimide hydrogels, augment soft tissue through a direct volume filling effect. Injections are placed into the subcutaneous fat. (See",
"      <a class=\"local\" href=\"#H15763919\">",
"       'Hydrogel polymers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Liquid injectable silicone exerts its effects through acting as a direct volume filler and a stimulant for new collagen formation. Only pure, medical grade silicone should be used for injection, and a microdroplet serial puncture technique should be used. When improper formulations or injection techniques are utilized, silicone can induce severe adverse effects. Liquid injectable silicone should be used only by expert and experienced injectors. (See",
"      <a class=\"local\" href=\"#H6313044\">",
"       'Liquid injectable silicone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autologous fat transfer provides soft tissue augmentation without the risk for allergic reactions. The degree persistence of fat in the treated site is variable and is dependent on multiple factors, such as clinician technique and treatment location. Fat embolus is a potential serious complication of this procedure. (See",
"      <a class=\"local\" href=\"#H875327\">",
"       'Autologous fat'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/1\">",
"      Lemperle G, Knapp TR, Sadick NS, Lemperle SM. ArteFill permanent injectable for soft tissue augmentation: I. Mechanism of action and injection techniques. Aesthetic Plast Surg 2010; 34:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/2\">",
"      Lemperle G, Romano JJ, Busso M. Soft tissue augmentation with artecoll: 10-year history, indications, techniques, and complications. Dermatol Surg 2003; 29:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/3\">",
"      Lemperle G, Sadick NS, Knapp TR, Lemperle SM. ArteFill permanent injectable for soft tissue augmentation: II. Indications and applications. Aesthetic Plast Surg 2010; 34:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/4\">",
"      Cohen SR, Holmes RE. Artecoll: a long-lasting injectable wrinkle filler material: Report of a controlled, randomized, multicenter clinical trial of 251 subjects. Plast Reconstr Surg 2004; 114:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/5\">",
"      Cohen SR, Berner CF, Busso M, et al. ArteFill: a long-lasting injectable wrinkle filler material--summary of the U.S. Food and Drug Administration trials and a progress report on 4- to 5-year outcomes. Plast Reconstr Surg 2006; 118:64S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/6\">",
"      Cohen SR, Berner CF, Busso M, et al. Five-year safety and efficacy of a novel polymethylmethacrylate aesthetic soft tissue filler for the correction of nasolabial folds. Dermatol Surg 2007; 33 Suppl 2:S222.",
"     </a>",
"    </li>",
"    <li>",
"     Artefill Instructions for Use. San Diego, CA: Suneva Medical, Inc; 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/8\">",
"      Bagal A, Dahiya R, Tsai V, Adamson PA. Clinical experience with polymethylmethacrylate microspheres (Artecoll) for soft-tissue augmentation: a retrospective review. Arch Facial Plast Surg 2007; 9:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/9\">",
"      Lemperle G, de Fazio S, Nicolau P. ArteFill: a third-generation permanent dermal filler and tissue stimulator. Clin Plast Surg 2006; 33:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/10\">",
"      Chrastil-LaTowsky B, Wesley NO, MacGregor JL, et al. Delayed inflammatory reaction to bio-alcamid polyacrylamide gel used for soft-tissue augmentation. Arch Dermatol 2009; 145:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/11\">",
"      Breiting V, Aasted A, J&oslash;rgensen A, et al. A study on patients treated with polyacrylamide hydrogel injection for facial corrections. Aesthetic Plast Surg 2004; 28:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/12\">",
"      von Buelow S, von Heimburg D, Pallua N. Efficacy and safety of polyacrylamide hydrogel for facial soft-tissue augmentation. Plast Reconstr Surg 2005; 116:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/13\">",
"      von Buelow S, Pallua N. Efficacy and safety of polyacrylamide hydrogel for facial soft-tissue augmentation in a 2-year follow-up: a prospective multicenter study for evaluation of safety and aesthetic results in 101 patients. Plast Reconstr Surg 2006; 118:85S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/14\">",
"      De Santis G, Jacob V, Baccarani A, et al. Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: a 2-year clinical experience. Plast Reconstr Surg 2008; 121:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/15\">",
"      Wolters M, Lampe H. Prospective multicenter study for evaluation of safety, efficacy, and esthetic results of cross-linked polyacrylamide hydrogel in 81 patients. Dermatol Surg 2009; 35 Suppl 1:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/16\">",
"      Narins RS, Coleman WP 3rd, Rohrich R, et al. 12-Month controlled study in the United States of the safety and efficacy of a permanent 2.5% polyacrylamide hydrogel soft-tissue filler. Dermatol Surg 2010; 36 Suppl 3:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/17\">",
"      Pallua N, Wolter TP. A 5-year assessment of safety and aesthetic results after facial soft-tissue augmentation with polyacrylamide hydrogel (Aquamid): a prospective multicenter study of 251 patients. Plast Reconstr Surg 2010; 125:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/18\">",
"      Negredo E, Puig J, Aldea D, et al. Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy. AIDS Res Hum Retroviruses 2009; 25:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/19\">",
"      Kawamura JY, Domaneschi C, Migliari DA, Sousa SO. Foreign body reaction due to skin filler: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/20\">",
"      Niedzielska I, Pajak J, Drugacz J. Late complications after polyacrylamide hydrogel injection into facial soft tissues. Aesthetic Plast Surg 2006; 30:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/21\">",
"      Goldman MP. Pressure-induced migration of a permanent soft tissue filler. Dermatol Surg 2009; 35 Suppl 1:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/22\">",
"      Alijotas-Reig J, Garcia-Gimenez V, Mir&oacute;-Mur F, Vilardell-Tarr&eacute;s M. Delayed immune-mediated adverse effects related to polyacrylamide dermal fillers: clinical findings, management, and follow-up. Dermatol Surg 2009; 35 Suppl 1:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/23\">",
"      Liu HL, Cheung WY. Complications of polyacrylamide hydrogel (PAAG) injection in facial augmentation. J Plast Reconstr Aesthet Surg 2010; 63:e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/24\">",
"      Protopapa C, Sito G, Caporale D, Cammarota N. Bio-Alcamid in drug-induced lipodystrophy. J Cosmet Laser Ther 2003; 5:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/25\">",
"      Treacy PJ, Goldberg DJ. Use of a biopolymer polyalkylimide filler for facial lipodystrophy in HIV-positive patients undergoing treatment with antiretroviral drugs. Dermatol Surg 2006; 32:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/26\">",
"      Lahiri A, Waters R. Experience with Bio-Alcamid, a new soft tissue endoprosthesis. J Plast Reconstr Aesthet Surg 2007; 60:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/27\">",
"      Loutfy MR, Raboud JM, Antoniou T, et al. Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients. AIDS 2007; 21:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/28\">",
"      Ramon Y, Fodor L, Ullmann Y. Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy. Dermatology 2007; 214:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/29\">",
"      H&ouml;nig J. Cheek augmentation with Bio-Alcamid in facial lipoatrophy in HIV seropositive patients. J Craniofac Surg 2008; 19:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/30\">",
"      Antoniou T, Raboud JM, Kovacs C, et al. Long-term efficacy and safety of polyalkylimide gel for the treatment of HIV-associated lipoatrophy. AIDS Care 2009; 21:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/31\">",
"      Pacini S, Ruggiero M, Morucci G, et al. Bio-alcamid: a novelty for reconstructive and cosmetic surgery. Ital J Anat Embryol 2002; 107:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/32\">",
"      Claoue BL, Rabineau P. The polyalkylimide gel: experience with Bio-Alcamid. Semin Cutan Med Surg 2004; 23:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/33\">",
"      Karim RB, Hage JJ, van Rozelaar L, et al. Complications of polyalkylimide 4% injections (Bio-Alcamid): a report of 18 cases. J Plast Reconstr Aesthet Surg 2006; 59:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/34\">",
"      Serrano C, Serrano S. [Delayed infection after Bio-alcamid implantation]. Actas Dermosifiliogr 2006; 97:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/35\">",
"      Goldan O, Georgiou I, Farber N, et al. Late-onset facial abscess formation after cosmetic soft tissue augmentation with bio-alcamid. Aesthet Surg J 2007; 27:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/36\">",
"      Goldan O, Georgiou I, Grabov-Nardini G, et al. Early and late complications after a nonabsorbable hydrogel polymer injection: a series of 14 patients and novel management. Dermatol Surg 2007; 33 Suppl 2:S199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/37\">",
"      G&oacute;mez-de la Fuente E, Alvarez-Fern&aacute;ndez JG, Pinedo F, et al. [Cutaneous adverse reaction to Bio-Alcamid implant]. Actas Dermosifiliogr 2007; 98:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/38\">",
"      Jones DH, Carruthers A, Fitzgerald R, et al. Late-appearing abscesses after injections of nonabsorbable hydrogel polymer for HIV-associated facial lipoatrophy. Dermatol Surg 2007; 33 Suppl 2:S193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/39\">",
"      Akrish S, Dayan D, Taicher S, et al. Foreign body granulomas after injection of Bio-alcamid for lip augmentation. Am J Otolaryngol 2009; 30:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/40\">",
"      Ross AH, Malhotra R. Long-term orbitofacial complications of polyalkylimide 4% (bio-alcamid). Ophthal Plast Reconstr Surg 2009; 25:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/41\">",
"      Jones DH. Semipermanent and permanent injectable fillers. Dermatol Clin 2009; 27:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/42\">",
"      Prather CL, Jones DH. Liquid injectable silicone for soft tissue augmentation. Dermatol Ther 2006; 19:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/43\">",
"      Hevia O. Six-year experience using 1,000-centistoke silicone oil in 916 patients for soft-tissue augmentation in a private practice setting. Dermatol Surg 2009; 35 Suppl 2:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/44\">",
"      Jones DH, Carruthers A, Orentreich D, et al. Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial. Dermatol Surg 2004; 30:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/45\">",
"      Moscona RA, Fodor L. A retrospective study on liquid injectable silicone for lip augmentation: long-term results and patient satisfaction. J Plast Reconstr Aesthet Surg 2010; 63:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/46\">",
"      Orentreich D, Leone AS. A case of HIV-associated facial lipoatrophy treated with 1000-cs liquid injectable silicone. Dermatol Surg 2004; 30:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/47\">",
"      Narins RS, Beer K. Liquid injectable silicone: a review of its history, immunology, technical considerations, complications, and potential. Plast Reconstr Surg 2006; 118:77S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/48\">",
"      Duffy DM. Liquid silicone for soft tissue augmentation. Dermatol Surg 2005; 31:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/49\">",
"      Balkin SW. Injectable silicone and the foot: a 41-year clinical and histologic history. Dermatol Surg 2005; 31:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/50\">",
"      Barnett JG, Barnett CR. Treatment of acne scars with liquid silicone injections: 30-year perspective. Dermatol Surg 2005; 31:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/51\">",
"      Zappi E, Barnett JG, Zappi M, Barnett CR. The long-term host response to liquid silicone injected during soft tissue augmentation procedures: a microscopic appraisal. Dermatol Surg 2007; 33 Suppl 2:S186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/52\">",
"      Wilkie TF. Late development of granuloma after liquid silicone injections. Plast Reconstr Surg 1977; 60:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/53\">",
"      Milojevic B. Complications after silicone injection therapy in aesthetic plastic surgery. Aesthetic Plast Surg 1982; 6:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/54\">",
"      Travis WD, Balogh K, Abraham JL. Silicone granulomas: report of three cases and review of the literature. Hum Pathol 1985; 16:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/55\">",
"      Granick MS, Solomon MP, Mosely LH, McGrath MH. Devastating granulomata of the lower extremities resulting from cosmetic injection of adulturated liquid silicone. Plast Reconstr Surg 1994; 94:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/56\">",
"      Rapaport MJ, Vinnik C, Zarem H. Injectable silicone: cause of facial nodules, cellulitis, ulceration, and migration. Aesthetic Plast Surg 1996; 20:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/57\">",
"      Ficarra G, Mosqueda-Taylor A, Carlos R. Silicone granuloma of the facial tissues: a report of seven cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 94:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/58\">",
"      Pimentel L, Barnadas M, Vidal D, et al. Simultaneous presentation of silicone and silica granuloma: a case report. Dermatology 2002; 205:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/59\">",
"      Poveda R, Bag&aacute;n JV, Murillo J, Jim&eacute;nez Y. Granulomatous facial reaction to injected cosmetic fillers--a presentation of five cases. Med Oral Patol Oral Cir Bucal 2006; 11:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/60\">",
"      Schwartzfarb EM, Hametti JM, Romanelli P, Ricotti C. Foreign body granuloma formation secondary to silicone injection. Dermatol Online J 2008; 14:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/61\">",
"      Altmeyer MD, Anderson LL, Wang AR. Silicone migration and granuloma formation. J Cosmet Dermatol 2009; 8:92.",
"     </a>",
"    </li>",
"    <li>",
"     Orentreich DS, Orentreich N. Injectable fluid silicone. In: Dermatologic surgery: Principles and Practice, 1st ed, Roenigk R, Roenigk HH (Eds), Marcel Dekker, New York 1989. p.1349.",
"    </li>",
"    <li>",
"     Duffy DM. Injectable liquid silicone: New perspectives. In: Tissue Augmentation in Clinical Practice: Procedures and Techniques, 1st ed, Klein A (Ed), Marcel Dekker, New York 1998. p.237.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/64\">",
"      Baumann LS, Halem ML. Lip silicone granulomatous foreign body reaction treated with aldara (imiquimod 5%). Dermatol Surg 2003; 29:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/65\">",
"      Arin MJ, B&auml;te J, Krieg T, Hunzelmann N. Silicone granuloma of the face treated with minocycline. J Am Acad Dermatol 2005; 52:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/66\">",
"      Pasternack FR, Fox LP, Engler DE. Silicone granulomas treated with etanercept. Arch Dermatol 2005; 141:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/67\">",
"      Alijotas-Reig J, Garcia-Gimenez V, Vilardell-Tarr&eacute;s M. Tacrolimus in the treatment of chronic and refractory late-onset immune-mediated adverse effects related to silicone injections. Dermatol Surg 2012; 38:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/68\">",
"      Orentreich DS. Liquid injectable silicone: techniques for soft tissue augmentation. Clin Plast Surg 2000; 27:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/69\">",
"      Coleman SR. Facial recontouring with lipostructure. Clin Plast Surg 1997; 24:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/70\">",
"      Butterwick KJ, Lack EA. Facial volume restoration with the fat autograft muscle injection technique. Dermatol Surg 2003; 29:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/71\">",
"      Donofrio LM. Structural autologous lipoaugmentation: a pan-facial technique. Dermatol Surg 2000; 26:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/72\">",
"      Donofrio LM. Techniques in facial fat grafting. Aesthet Surg J 2008; 28:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/73\">",
"      Glasgold M, Lam SM, Glasgold R. Autologous fat grafting for cosmetic enhancement of the perioral region. Facial Plast Surg Clin North Am 2007; 15:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/74\">",
"      Kanchwala SK, Glatt BS, Conant EF, Bucky LP. Autologous fat grafting to the reconstructed breast: the management of acquired contour deformities. Plast Reconstr Surg 2009; 124:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/75\">",
"      Pereira LH, Nicaretta B, Sterodimas A. Correction of liposuction sequelae by autologous fat transplantation. Aesthetic Plast Surg 2011; 35:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/76\">",
"      Ersek RA. Transplantation of purified autologous fat: a 3-year follow-up is disappointing. Plast Reconstr Surg 1991; 87:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/77\">",
"      Coleman SR. Long-term survival of fat transplants: controlled demonstrations. Aesthetic Plast Surg 1995; 19:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/78\">",
"      Fulton JE, Suarez M, Silverton K, Barnes T. Small volume fat transfer. Dermatol Surg 1998; 24:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/79\">",
"      Fournier PF. Fat grafting: my technique. Dermatol Surg 2000; 26:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/80\">",
"      Moscatello DK, Schiavi J, Marquart JD, Lawrence N. Collagenase-assisted fat dissociation for autologous fat transfer. Dermatol Surg 2008; 34:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/81\">",
"      Cervelli V, Palla L, Pascali M, et al. Autologous platelet-rich plasma mixed with purified fat graft in aesthetic plastic surgery. Aesthetic Plast Surg 2009; 33:716.",
"     </a>",
"    </li>",
"    <li>",
"     Alexander RW. Use of platelet-rich plasma to enhance effectiveness of autologous fat grafting. In: Autologous Fat Transfer: Art, Science, and Clinical Practice, Shiffman MA (Ed), Springer, Heidelberg 2010. p.87.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/83\">",
"      Yoshimura K, Sato K, Aoi N, et al. Cell-assisted lipotransfer for facial lipoatrophy: efficacy of clinical use of adipose-derived stem cells. Dermatol Surg 2008; 34:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/84\">",
"      Sterodimas A, de Faria J, Nicaretta B, et al. Cell-assisted lipotransfer. Aesthet Surg J 2010; 30:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/85\">",
"      Eremia S, Newman N. Long-term follow-up after autologous fat grafting: analysis of results from 116 patients followed at least 12 months after receiving the last of a minimum of two treatments. Dermatol Surg 2000; 26:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/86\">",
"      Sterodimas A, de Faria J, Nicaretta B, Pitanguy I. Tissue engineering with adipose-derived stem cells (ADSCs): current and future applications. J Plast Reconstr Aesthet Surg 2010; 63:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/87\">",
"      Cheng JT, Perkins SW, Hamilton MM. Collagen and injectable fillers. Otolaryngol Clin North Am 2002; 35:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/88\">",
"      Teimourian B. Blindness following fat injections. Plast Reconstr Surg 1988; 82:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/89\">",
"      Dreizen NG, Framm L. Sudden unilateral visual loss after autologous fat injection into the glabellar area. Am J Ophthalmol 1989; 107:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/90\">",
"      Egido JA, Arroyo R, Marcos A, Jim&eacute;nez-Alfaro I. Middle cerebral artery embolism and unilateral visual loss after autologous fat injection into the glabellar area. Stroke 1993; 24:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/91\">",
"      Feinendegen DL, Baumgartner RW, Schroth G, et al. Middle cerebral artery occlusion AND ocular fat embolism after autologous fat injection in the face. J Neurol 1998; 245:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/92\">",
"      Danesh-Meyer HV, Savino PJ, Sergott RC. Case reports and small case series: ocular and cerebral ischemia following facial injection of autologous fat. Arch Ophthalmol 2001; 119:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/93\">",
"      Yoon SS, Chang DI, Chung KC. Acute fatal stroke immediately following autologous fat injection into the face. Neurology 2003; 61:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/94\">",
"      Thaunat O, Thaler F, Loirat P, et al. Cerebral fat embolism induced by facial fat injection. Plast Reconstr Surg 2004; 113:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/95\">",
"      Mori K, Ohta K, Nagano S, et al. [A case of ophthalmic artery obstruction following autologous fat injection in the glabellar area]. Nihon Ganka Gakkai Zasshi 2007; 111:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/96\">",
"      Park SH, Sun HJ, Choi KS. Sudden unilateral visual loss after autologous fat injection into the nasolabial fold. Clin Ophthalmol 2008; 2:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/97\">",
"      Gleeson CM, Lucas S, Langrish CJ, Barlow RJ. Acute fatal fat tissue embolism after autologous fat transfer in a patient with lupus profundus. Dermatol Surg 2011; 37:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26024/abstract/98\">",
"      Park YH, Kim KS. Images in clinical medicine. Blindness after fat injections. N Engl J Med 2011; 365:2220.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13652 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_26_26024=[""].join("\n");
var outline_f25_26_26024=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H881865\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H879724\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3502728\">",
"      PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15763905\">",
"      POLYMETHYLMETHACRYLATE MICROSPHERES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H873135\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H873242\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H873142\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H873149\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15763919\">",
"      HYDROGEL POLYMERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H873899\">",
"      Polyacrylamide hydrogel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H874204\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H874220\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H874440\">",
"      - Use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H874302\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8872500\">",
"      Polyalkylimide hydrogel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H882078\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H882085\">",
"      - Efficacy and use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H882092\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6313044\">",
"      LIQUID INJECTABLE SILICONE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6313086\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6313093\">",
"      Efficacy and safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6313100\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H875327\">",
"      AUTOLOGOUS FAT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H881865\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13652\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13652|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/19/23858\" title=\"figure 1\">",
"      Placement of injectable soft tissue fillers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27049?source=related_link\">",
"      Injectable soft tissue fillers: Overview of clinical use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=related_link\">",
"      Injectable soft tissue fillers: Semipermanent agents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_26_26025="Unipolar minor depression in adults: Epidemiology, clinical presentation, and diagnosis";
var content_f25_26_26025=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unipolar minor depression in adults: Epidemiology, clinical presentation, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/26/26025/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/26/26025/contributors\">",
"     Wayne Katon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/26/26025/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/26/26025/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/26/26025/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/26/26025/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/26/26025/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H796041971\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The continuum of clinical depression increases in severity from symptoms to minor depression to major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Minor depression is characterized by fewer symptoms than major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/4\">",
"     4",
"    </a>",
"    ], as well as shorter episodes, less comorbidity, less psychosocial and physical impairment, and fewer recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, minor depression is a common syndrome that causes clinically significant distress and impairs functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. In addition, minor depression is associated with somatic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/7,11\">",
"     7,11",
"    </a>",
"    ], comorbid psychiatric and general medical disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/7,11\">",
"     7,11",
"    </a>",
"    ], and substantial health care utilization and costs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/1,11,12\">",
"     1,11,12",
"    </a>",
"    ]. Most patients with minor depression do not seek treatment from a mental health clinician but are frequently seen in primary care [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. Although minor depression is at least as prevalent as major depression, fewer patients with minor depression are accurately diagnosed by primary care clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/7,14\">",
"     7,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the epidemiology, pathogenesis, clinical manifestations, assessment, diagnosis, and differential diagnosis of minor depression. The treatment of minor depression is discussed separately, as are the clinical features, diagnosis, treatment, and prognosis of major depression:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35015?source=see_link\">",
"       \"Unipolar minor depression in adults: Management and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38201?source=see_link\">",
"       \"Unipolar depression in adults: Prognosis and course of illness\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H796041978\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"depression\" can refer to a mood state, syndrome, or specific disorder; these depressive clinical states are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of depression\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many terms are used to describe clinically significant depressive syndromes that fall short of meeting criteria for major depression, including [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/13,15\">",
"     13,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Minor depression",
"     </li>",
"     <li>",
"      Mild depression",
"     </li>",
"     <li>",
"      Subthreshold depression",
"     </li>",
"     <li>",
"      Subsyndromal depression",
"     </li>",
"     <li>",
"      Subclinical depression",
"     </li>",
"     <li>",
"      Depressive symptoms",
"     </li>",
"     <li>",
"      Depressive disorder not otherwise specified",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The definition of minor depression varies among different studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/13\">",
"     13",
"    </a>",
"    ]. In the most widely used definitions, the number of concurrent symptoms ranges from one to three [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/1,16\">",
"     1,16",
"    </a>",
"    ] or two to four [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/2,8\">",
"     2,8",
"    </a>",
"    ], the symptoms cause clinically significant distress or psychosocial impairment, and the minimum duration of the syndrome is two to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/13,17,18\">",
"     13,17,18",
"    </a>",
"    ]. The diagnosis of minor depression is discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H1839470\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H796041985\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1839384\">",
"    <span class=\"h2\">",
"     General population",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated prevalence of minor depression in the general population varies among different countries:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review found that the estimated point prevalence in the United States was 2 to 5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/19\">",
"       19",
"      </a>",
"      ], and two nationally representative epidemiologic studies in the United States (N = 43,093 and 8098) estimated that the lifetime prevalence was 9 to 10 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/2,16\">",
"       2,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of nationally representative surveys in 68 countries (United States not included) with 252,503 respondents estimated that the one-year prevalence was 2.8 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/1\">",
"       1",
"      </a>",
"      ]; the prevalence among different countries ranged from 0.1 to 8.6 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1839391\">",
"    <span class=\"h2\">",
"     Clinical settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among primary care patients, the observed point prevalence of minor depression ranges from 6 to 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/6,7,9,11,20\">",
"     6,7,9,11,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5854257\">",
"    <span class=\"h2\">",
"     Sociodemographic correlates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon large, nationally representative epidemiologic studies in the United States and many other countries, as well as clinical studies, minor depression is consistently more prevalent among females and previously married individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/1,2,16,20\">",
"     1,2,16,20",
"    </a>",
"    ]. In addition, minor depression is consistently associated with psychosocial impairment (in studies that do not require impairment or significant distress to diagnose the disorder) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/16,21\">",
"     16,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A community study (N = 2393) found that occupational and interpersonal functioning was worse among individuals with minor depression than individuals with no depressive symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of primary care patients found that occupational and marital functioning were worse in patients with minor depression (N = 91), compared to patients with no psychiatric symptoms (N = 606) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An observational study of general medical patients found that occupational and social functioning were each worse in patients with minor depression than patients with no chronic condition such as arthritis, diabetes, or hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H796041992\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology and pathogenesis of minor depression is not known.",
"   </p>",
"   <p>",
"    Knowledge about the genetics of minor depression is limited to findings from two community studies, which found that the disorder does not aggregate within families. Both studies enrolled individuals with a lifetime history of minor depression (but no major depression or dysthymia) plus their first degree relatives, as well as controls without depression (minor depression, major depression, or dysthymia) plus their first degree relatives:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, the lifetime prevalence of minor depression was similar among family members of probands with minor depression compared with family members of controls (9.4 versus 9.0 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the second study, the lifetime prevalence of minor depression was comparable among family members of probands with minor depression compared with family members of controls (odds ratio 1.6, 95% CI 0.9-2.6) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Structural neuroimaging studies have identified abnormalities associated with minor depression, but it is not clear if these findings represent etiologic causes or sequelae because the studies investigated subjects after they developed symptoms. One study compared brain magnetic resonance images (MRI) collected in 21 community dwelling adults (mean age 51 years) with current minor depression (and no prior psychiatric or neurologic history) and 21 matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/23\">",
"     23",
"    </a>",
"    ]. The gray matter volume of the right and left anterior cingulate gyri and the right rectal gyrus were smaller in depressed females compared with female controls; no differences were observed between depressed males and control males. Another MRI study in 96 children and adolescents (age 7 to 17 years) found that the volume of the rostral anterior cingulate cortex was smaller bilaterally in boys with subclinical depressive symptoms than boys with no depressive symptoms; no difference was observed between depressed and nondepressed girls [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1839455\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications that are associated with depressive symptoms include glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    , and interferons [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Other medications that increase the risk of depressive symptoms are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef87554 \" href=\"UTD.htm?34/1/34843\">",
"     table 1",
"    </a>",
"    ). Abuse of alcohol and stimulants (eg, methamphetamine and cocaine) can also cause minor depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26204824\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression exists along a continuum, and minor depression is distinguished from major depression for purposes of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35015?source=see_link\">",
"     \"Unipolar minor depression in adults: Management and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An episode of minor depression is generally defined as a period lasting at least two weeks, with two to four of the following symptoms: depressed mood, loss of interest or pleasure in most activities, insomnia or hypersomnia, change in appetite or weight, psychomotor retardation or agitation, low energy, poor concentration, thoughts of worthlessness or guilt, and recurrent thoughts about death or suicide. The episode of minor depression is unipolar if the patient has no history of mania, mixed mania, or hypomania [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86895891\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of minor depression are pleomorphic, and can include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Somatic symptoms",
"      </strong>",
"      &ndash; Somatic symptoms are common in minor depression; in a study of 162 patients treated at specialty mood disorder clinics, somatic symptoms were present at baseline in 61 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/19\">",
"       19",
"      </a>",
"      ]. Among primary care patients with minor depression, common somatic symptoms include [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Abdominal discomfort (constipation, diarrhea, indigestion, gas, nausea, pain, or vomiting)",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Dizziness",
"     </li>",
"     <li>",
"      Dyspnea",
"     </li>",
"     <li>",
"      Fainting",
"     </li>",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Headache",
"     </li>",
"     <li>",
"      Insomnia",
"     </li>",
"     <li>",
"      Menstrual problems",
"     </li>",
"     <li>",
"      Muscle tension",
"     </li>",
"     <li>",
"      Pain (back, joint, or limb)",
"     </li>",
"     <li>",
"      Palpitations",
"     </li>",
"     <li>",
"      Sexual problems",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Primary care based studies of minor depression show a direct correlation between the number of depressive symptoms and somatic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Emotional symptoms",
"      </strong>",
"      &ndash; Many patients with minor depression present with depressed mood, crying spells, lack of pleasure in usual activities, or irritability [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/19,30\">",
"       19,30",
"      </a>",
"      ]. Patients may also present with symptoms of anxiety such as worry, tenseness, and feeling on edge.",
"     </li>",
"     <li>",
"      <strong>",
"       Cognitive symptoms",
"      </strong>",
"      &ndash; Minor depression can present with impaired concentration, memory, and decision making, as well as thoughts of worthlessness, hopelessness, and helplessness [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/19,30\">",
"       19,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Neurovegetative symptoms",
"      </strong>",
"      &ndash; Minor depression can present with insomnia or hypersomnia, increased or decreased appetite, and psychomotor agitation (eg, inability to sit still or wringing one's hands) or psychomotor retardation (feeling slowed down) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Suicidality",
"      </strong>",
"      &ndash; Suicidal ideation or behavior is common in minor depression [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/30-32\">",
"       30-32",
"      </a>",
"      ]. An epidemiologic survey found that a lifetime history of suicide attempts was greater among individuals with minor depression (N = 4337) than individuals with no depression (N = 13,068) (5 versus 1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/33\">",
"       33",
"      </a>",
"      ], and a treatment study (N = 162) found that at baseline, suicidal ideation was present in 12 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/19\">",
"       19",
"      </a>",
"      ]. In addition, patients with suicidal ideation have the highest odds of subsequently developing major depression, compared to patients with other symptoms of minor depression [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H796041999\">",
"       'Course of illness'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The severity of minor depression ranges from mild to moderately severe episodes that overlap with major depression, based upon clinical ratings of patients with standard assessments such as the Hamilton Rating Scale for Depression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many patients with minor depression have a past history of major depressive episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/35\">",
"     35",
"    </a>",
"    ]. As an example, a treatment study of 162 patients with minor depression found that major depression had previously occurred in 32 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, minor depression may occur as a prodromal, intra-episodic, or residual stage of major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20072886\">",
"    <span class=\"h1\">",
"     COMORBIDITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26204853\">",
"    <span class=\"h2\">",
"     Psychiatric comorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychiatric comorbidity is common in minor depression. An epidemiologic study of 810 individuals with minor depression found a lifetime history of at least one comorbid disorder in 54 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/2\">",
"     2",
"    </a>",
"    ]. Another epidemiologic study found that other psychiatric disorders were present in twice as many individuals with minor depression (N = 4337) compared to individuals with no depression (N = 13,068) (30 versus 15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/33\">",
"     33",
"    </a>",
"    ]. In two studies of primary care patients with minor depression (N = 83 and 91), comorbidity was present in 37 and 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/9,11\">",
"     9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an epidemiologic study, the lifetime prevalence of the following disorders was greater among individuals with minor depression (N = 3232) than individuals with no depressive symptoms (N = 23,214) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anxiety disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Panic disorder",
"     </li>",
"     <li>",
"      Social phobia",
"     </li>",
"     <li>",
"      Specific phobia",
"     </li>",
"     <li>",
"      Generalized anxiety disorder",
"     </li>",
"     <li>",
"      Posttraumatic stress disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alcohol use disorder",
"     </li>",
"     <li>",
"      Drug use disorder",
"     </li>",
"     <li>",
"      Personality disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other psychiatric comorbidities in patients with minor depression include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/33,37,38\">",
"     33,37,38",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Somatoform disorders",
"     </li>",
"     <li>",
"      Cognitive disorders",
"     </li>",
"     <li>",
"      Eating disorders",
"     </li>",
"     <li>",
"      Sleep disorders (eg, sleep apnea)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26205068\">",
"    <span class=\"h2\">",
"     General medical comorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor depression often occurs in patients with general medical disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/5,7,10\">",
"     5,7,10",
"    </a>",
"    ]. A nationally representative epidemiologic survey found that among individuals with one chronic, general medical condition (eg, asthma, blindness, cancer, chronic kidney disease, deafness, hepatitis, HIV infection, hypothyroidism, hypertension, or peptic ulcer disease), the estimated one-year prevalence of minor depression was 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/2\">",
"     2",
"    </a>",
"    ]. In a meta-analysis of 10 community or primary care studies (N = 51,220), the prevalence of depression was higher in patients with type 2 diabetes mellitus than controls without diabetes (18 versus 10 percent); heterogeneity was moderate to large [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/39\">",
"     39",
"    </a>",
"    ]. Other general medical illnesses associated with depression include coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/40\">",
"     40",
"    </a>",
"    ], inflammatory diseases such as rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/41\">",
"     41",
"    </a>",
"    ] and systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/42\">",
"     42",
"    </a>",
"    ], and neurologic disorders (eg, dementia, epilepsy, multiple sclerosis, Parkinson disease, and stroke) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between minor depression and general medical illness may be bidirectional [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/44\">",
"     44",
"    </a>",
"    ]. Minor depression is associated with increased rates of smoking, lack of physical exercise, poor diet, and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]; these health risk behaviors may lead to chronic medical illnesses (eg, diabetes and coronary heart disease). In addition, depressive symptoms may be associated with increased cortisol levels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/47\">",
"     47",
"    </a>",
"    ] and inflammatory factors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/48\">",
"     48",
"    </a>",
"    ], as well as poor adherence to self care regimens (diet and exercise), which may hasten onset of chronic general medical illnesses. Conversely, chronic illnesses are associated with functional impairment that may precipitate or exacerbate depression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If minor depression is the direct physiologic consequence of a general medical disorder, the diagnosis is mood disorder due to a general medical condition with depressive features, rather than minor depression. (See",
"    <a class=\"local\" href=\"#H1839404\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H796041999\">",
"    <span class=\"h1\">",
"     COURSE OF ILLNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective community studies indicate that many episodes of minor depressive eventually resolve:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of minor depression (N = 176) found that during follow-up lasting one year, remission occurred in 37 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Two studies (N = 3232 and 435) found that during follow-up lasting three years, remission occurred in 76 and 59 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/16,49\">",
"       16,49",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nevertheless, minor depression can persist or recur:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two prospective community studies identified 3232 and 435 individuals with minor depression at baseline; three years later, minor depression was observed in 12 and 19 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/16,49\">",
"       16,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective study of minor depression in primary care patients (N = 59) found that at five year follow-up, minor depression was present in 19 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective, nationally representative survey of 810 individuals with a lifetime history of minor depression found that multiple episodes had occurred in 72 percent; the mean number of episodes was nine, and the average length of the longest episode was 21 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Minor depression can also progress to major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/34\">",
"     34",
"    </a>",
"    ]. A review of 20 prospective studies (N = 43,198) that included community samples and primary care patients found that in most studies, major depression was more likely to occur in subjects with minor depression than subjects without minor depression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/50\">",
"     50",
"    </a>",
"    ]. Specific studies have shown the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective community study of minor depression (N = 3232) found that during follow-up lasting three years, major depression occurred in more individuals with minor depression than individuals with no depressive symptoms (9 versus 5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A one-year prospective study of 4285 primary care patients (identified in an epidemiologic study) found that the risk of developing major depression or dysthymia was six times greater among patients with two depressive symptoms at baseline compared to patients with no symptoms (relative risk 6, 95% CI 2-14). Among patients with three depressive symptoms at baseline, the risk was nine times greater (RR 9, 95% CI 3-26) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, patients with minor depression are at increased risk of developing other psychiatric disorders (eg, anxiety disorders) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/16,30\">",
"     16,30",
"    </a>",
"    ]. A prospective community study of adolescents who were followed into adulthood (age 22 or 33 years) found that compared to adolescents without minor depression (N = 694), adolescents with minor depression (N = 62) were more likely to develop disruptive disorders (eg, attention deficit disorder), eating disorders, and personality disorders, as well as major depressive episodes and anxiety disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26204572\">",
"    <span class=\"h1\">",
"     ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial assessment for minor depression includes a psychiatric history and mental status examination, as well as a general medical history, physical examination, and focused laboratory tests based upon findings from the history and physical examination. Some clinicians routinely screen for general medical disorders with a basic panel of tests (eg, thyrotropin [TSH], complete blood count, electrolytes, glucose, calcium, phosphate, serum urea nitrogen, creatinine, liver function tests, and urine toxicology for drugs of abuse) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The psychiatric history should emphasize:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptoms of depression (",
"      <a class=\"graphic graphic_table graphicRef87557 \" href=\"UTD.htm?8/23/8573\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chronological history of depressive symptoms and disorders",
"     </li>",
"     <li>",
"      Anxiety, personality, and substance use disorders",
"     </li>",
"     <li>",
"      Medications",
"     </li>",
"     <li>",
"      Prior history of mood and anxiety disorders",
"     </li>",
"     <li>",
"      Current and chronic psychosocial stressors",
"     </li>",
"     <li>",
"      Level of social support",
"     </li>",
"     <li>",
"      Family history of mood and anxiety disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient's appearance during the interview may also provide clues to depression, such as sadness, tearfulness, irritability, and psychomotor retardation or agitation. In addition, it is often helpful to query family members about the patient's clinical status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H866458\">",
"    <span class=\"h2\">",
"     Suicide",
"    </span>",
"    &nbsp;&mdash;&nbsp;All depressed patients should be assessed for suicidal ideation (including plans) and behavior. Initially inquiring about hopelessness can lead to a discussion of suicidal thoughts. If suicidal ideation is present, clinicians should ask about specific plans. Gauging the risk associated with the suicide plan helps determine if inpatient psychiatric care is necessary and whether others (eg, family members or the police) need to remove potentially lethal items from the house (eg, guns).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26204648\">",
"    <span class=\"h2\">",
"     Screening tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several instruments are available to screen for minor depression, including the Patient Health Questionnaire &ndash; Nine Item (PHQ-9) (",
"    <a class=\"graphic graphic_table graphicRef59307 \" href=\"UTD.htm?14/12/14541\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/54\">",
"     54",
"    </a>",
"    ]. A score of 5 to 9 indicates a high probability of minor depression. However, the PHQ-9 does not generate a diagnosis of minor depression; thus, patients who screen positive require a clinical interview to make the diagnosis. Screening for depression, the PHQ-9, and reasonable alternatives to the PHQ-9 are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical manifestations and diagnosis of depression\", section on 'Screening for depression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4745?source=see_link&amp;anchor=H100014092#H100014092\">",
"     \"Using scales to monitor symptoms and treatment of depression (measurement based care)\", section on 'Patient Health Questionnaire - Nine Item'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1839470\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest diagnosing minor depressive episodes according to the tentative criteria proposed for additional study in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) (",
"    <a class=\"graphic graphic_table graphicRef87557 \" href=\"UTD.htm?8/23/8573\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/4\">",
"     4",
"    </a>",
"    ]. A reasonable alternative are the criteria for \"mild depressive episode\" in the World Health Organization's International Classification of Diseases-10th Revision (ICD-10) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to DSM-IV-TR, the diagnosis of minor depression requires each of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two to four of the following symptoms have been present during the same two week period:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Dysphoria",
"     </li>",
"     <li>",
"      Anhedonia",
"     </li>",
"     <li>",
"      Appetite or weight change",
"     </li>",
"     <li>",
"      Insomnia or hypersomnia",
"     </li>",
"     <li>",
"      Psychomotor agitation or retardation",
"     </li>",
"     <li>",
"      Anergia",
"     </li>",
"     <li>",
"      Thoughts of worthlessness or inappropriate guilt",
"     </li>",
"     <li>",
"      Impaired concentration or memory",
"     </li>",
"     <li>",
"      Recurrent thoughts of death or suicide, or suicide attempt",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the symptoms includes dysphoria or anhedonia",
"     </li>",
"     <li>",
"      The symptoms cause clinically significant distress or psychosocial impairment",
"     </li>",
"     <li>",
"      The symptoms are not due to the physiologic effects of a substance or general medical condition",
"     </li>",
"     <li>",
"      Dysthymic disorder and cyclothymic disorder are not present (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations and diagnosis of depression\", section on 'Dysthymic disorder'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The symptoms are not better accounted for by bereavement (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31190?source=see_link\">",
"       \"Grief and bereavement\"",
"      </a>",
"      ) &nbsp;",
"     </li>",
"     <li>",
"      There has never been a major depressive, manic, hypomanic, or mixed episode",
"     </li>",
"     <li>",
"      The mood disturbance does not occur exclusively during a psychotic disorder (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of psychosis\", section on 'Psychotic disorders'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the ICD-10 diagnostic criteria for a mild depressive episode [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/55\">",
"     55",
"    </a>",
"    ] overlap with the DSM-IV-TR criteria for minor depression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/4\">",
"     4",
"    </a>",
"    ], the primary differences are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ICD-10 mild depressive episodes require a minimum of four depressive symptoms and may include as many as 10 depressive symptoms; by contrast, the minimum number for DSM-IV-TR minor depression is two and the maximum is four",
"     </li>",
"     <li>",
"      ICD-10 describes two subtypes of mild depressive episodes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      With somatic symptoms &ndash; The depressive syndrome is worse in the morning and dominated by symptoms such as anhedonia, early morning awakening, psychomotor retardation or agitation, loss of appetite or weight, and loss of libido",
"     </li>",
"     <li>",
"      Without somatic symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These subtypes are not applied to DSM-IV-TR episodes of minor depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1839404\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of minor depression overlap with symptoms of other depressive disorders, especially major depression and dysthymia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Major depression",
"      </strong>",
"      &ndash; Each of the symptoms that can occur during an episode of minor depression (",
"      <a class=\"graphic graphic_table graphicRef87557 \" href=\"UTD.htm?8/23/8573\">",
"       table 2",
"      </a>",
"      ) can also occur during major depression (",
"      <a class=\"graphic graphic_table graphicRef70852 \" href=\"UTD.htm?17/21/17756\">",
"       table 4",
"      </a>",
"      ), and both syndromes require a minimum duration of two weeks and cause clinically significant distress or psychosocial impairment. The two disorders are distinguished by the number of symptoms that are present; minor depression is diagnosed if two to four depressive symptoms are present, whereas major depression requires a minimum of five symptoms. Major depression that improves such that two to four residual symptoms are still present is classified as major depression in partial remission, rather than minor depression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations and diagnosis of depression\", section on 'Major depression'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Dysthymic disorder",
"      </strong>",
"      &ndash; Minor depression and dysthymic disorder can both present with two to four depressive symptoms, but they are distinguished by their duration. If the symptoms persist for at least two years, dysthymic disorder is diagnosed, whereas minor depression is diagnosed if the symptoms have been present for less than two years. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations and diagnosis of depression\", section on 'Dysthymic disorder'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Minor depression and dysthymic disorder are treated differently. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35015?source=see_link\">",
"       \"Unipolar minor depression in adults: Management and treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link&amp;anchor=H524936#H524936\">",
"       \"Initial treatment of depression in adults\", section on 'Dysthymic disorder'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Adjustment disorder with depressed mood",
"      </strong>",
"      &ndash; If two to four depressive symptoms occur within three months of onset of one or more psychosocial stressors, the diagnosis is adjustment disorder with depressed mood, rather than minor depression. By definition, adjustment disorders resolve within six months once the stressor or its consequences has terminated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link&amp;anchor=H260614653#H260614653\">",
"       \"Clinical manifestations and diagnosis of depression\", section on 'Adjustment disorder with depressed mood'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Minor depression and adjustment disorder are often managed in the same manner. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35015?source=see_link\">",
"       \"Unipolar minor depression in adults: Management and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Mood disorder due to a general medical condition with depressive features",
"      </strong>",
"      &ndash; If two to four depressive symptoms (including depressed mood",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diminished interest in activities) are the direct physiologic consequence of a general medical disorder, the diagnosis is mood disorder due to a general medical condition with depressive features, rather than minor depression. Many general medical conditions can cause or mimic a depressive syndrome, especially if fatigue is present (",
"      <a class=\"graphic graphic_table graphicRef56425 \" href=\"UTD.htm?4/7/4221\">",
"       table 5",
"      </a>",
"      ). Examples of illnesses to be distinguished from minor depression include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypothyroidism, which is characterized by a slowing of metabolic processes (eg, fatigue, slow movement, slow speech, cold intolerance, constipation, and weight gain) and by accumulation of matrix glycosaminoglycans in the interstitial spaces of many tissues (eg, coarse hair and skin, puffy facies, enlargement of the tongue, and hoarseness) (",
"      <a class=\"graphic graphic_table graphicRef62676 \" href=\"UTD.htm?41/41/42651\">",
"       table 6",
"      </a>",
"      ). Diagnosis of hypothyroidism relies heavily upon laboratory tests, including thyrotropin (TSH) and free thyroxine (T4). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"       \"Diagnosis of and screening for hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Parkinson disease, which is characterized by bradykinesia, gait disturbance, rest tremor, and rigidity, and diagnosed by the history and physical examination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link\">",
"       \"Diagnosis of Parkinson disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stroke, which is characterized by neurologic dysfunction, depending upon pathophysiologic process (",
"      <a class=\"graphic graphic_table graphicRef69907 \" href=\"UTD.htm?42/25/43419\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link\">",
"       \"Overview of the evaluation of stroke\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus, which is characterized by fatigue, weight loss, fever, photosensitive rash, arthralgia or arthritis, Raynaud phenomenon, serositis, nephritis, and phlebitis, as well as abnormal laboratory findings such as positive antinuclear antibodies (",
"      <a class=\"graphic graphic_table graphicRef86633 \" href=\"UTD.htm?1/31/1535\">",
"       table 8",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link\">",
"       \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Substance-induced mood disorder with depressive features",
"      </strong>",
"      &ndash; A depressive syndrome of two to four symptoms can occur in both minor depression and substance-induced mood disorder. The two disorders are treated differently. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35015?source=see_link\">",
"       \"Unipolar minor depression in adults: Management and treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2936?source=see_link\">",
"       \"Clinical management of substance dependence across the continuum of care\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=see_link\">",
"       \"Ambulatory alcohol detoxification\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If the depressive syndrome occurs during or within a month of intoxication or withdrawal from a drug of abuse (eg, alcohol or cocaine), or if it is due to the side effects of a medication (eg, steroids) and is judged to be etiologically related to the mood disturbance, the syndrome is classified as a substance induced mood disorder with depressive features, rather than minor depression [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26025/abstract/4\">",
"       4",
"      </a>",
"      ]. Evidence that the depressive syndrome may be better accounted for by minor depression includes the following clinical features:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Minor depression precedes onset of the substance use",
"     </li>",
"     <li>",
"      The depressive symptoms persist for a substantial period of time (eg, one month) after intoxication or withdrawal from the substance",
"     </li>",
"     <li>",
"      History of recurrent episodes of minor depression",
"     </li>",
"     <li>",
"      Family history of mood disorders &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H796042097\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The spectrum of clinical depression increases in severity from symptoms to minor depression to major depression. (See",
"      <a class=\"local\" href=\"#H796041971\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The term \"depression\" refers to different types of clinical states. Clinically significant depressive syndromes that fall short of meeting criteria for major depression are often classified as minor depression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations and diagnosis of depression\", section on 'Terminology'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H796041978\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nationally representative epidemiologic studies in the United States estimate that the lifetime prevalence of minor depression in the general population is 9 to 10 percent. Comparable surveys in 68 countries (United States not included) estimate that the one-year prevalence of minor depression is 2.8 percent. In primary care patients, the observed point prevalence ranges from 6 to 16 percent. Minor depression is consistently more prevalent among females and previously married individuals and is consistently associated with psychosocial impairment. (See",
"      <a class=\"local\" href=\"#H796041985\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology and pathogenesis of minor depression is not known. Family studies indicate that the disorder does not aggregate within families. Several medications are associated with depressive symptoms (",
"      <a class=\"graphic graphic_table graphicRef87554 \" href=\"UTD.htm?34/1/34843\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H796041992\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of minor depression often includes somatic symptoms as well as emotional, cognitive, neurovegetative symptoms, and suicidality. Minor depression frequently occurs in patients with comorbid anxiety, substance use, personality, and general medical disorders. (See",
"      <a class=\"local\" href=\"#H26204824\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although many episodes of minor depression eventually resolve, the disorder can persist or recur and can also progress to major depression. In addition, patients with minor depression are at increased risk of developing other psychiatric disorders (eg, anxiety disorders). (See",
"      <a class=\"local\" href=\"#H796041999\">",
"       'Course of illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial assessment for minor depression includes a psychiatric history and mental status examination, as well as a general medical history, physical examination, and focused laboratory tests. The psychiatric history should emphasize symptoms of depression, suicidal ideation and behavior, chronological history of depressive symptoms and disorders, other psychiatric disorders, medications, prior history of mood and anxiety disorders, psychosocial stressors, level of social support, and family history of mood and anxiety disorders. The Patient Health Questionnaire &ndash; Nine Item (",
"      <a class=\"graphic graphic_table graphicRef59307 \" href=\"UTD.htm?14/12/14541\">",
"       table 3",
"      </a>",
"      ) can be used to screen for minor depression. (See",
"      <a class=\"local\" href=\"#H26204572\">",
"       'Assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minor depressive episodes are generally diagnosed according to the criteria in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) (",
"      <a class=\"graphic graphic_table graphicRef87557 \" href=\"UTD.htm?8/23/8573\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1839470\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of minor depression overlap with symptoms of other depressive disorders, including major depression, dysthymia, adjustment disorder with depressed mood, substance-Induced mood disorder with depressive features, and mood disorder due to a general medical condition with depressive features, including neurologic disorders (eg, Parkinson disease or stroke), endocrine disorders (eg, hypothyroidism), infections (eg, HIV), and autoimmune diseases (eg, systemic lupus erythematosus). (See",
"      <a class=\"local\" href=\"#H1839404\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/1\">",
"      Ayuso-Mateos JL, Nuevo R, Verdes E, et al. From depressive symptoms to depressive disorders: the relevance of thresholds. Br J Psychiatry 2010; 196:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/2\">",
"      Kessler RC, Zhao S, Blazer DG, Swartz M. Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey. J Affect Disord 1997; 45:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/3\">",
"      Lewinsohn PM, Klein DN, Durbin EC, et al. Family study of subthreshold depressive symptoms: risk factor for MDD? J Affect Disord 2003; 77:149.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/5\">",
"      Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 1989; 262:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/6\">",
"      Williams JW Jr, Kerber CA, Mulrow CD, et al. Depressive disorders in primary care: prevalence, functional disability, and identification. J Gen Intern Med 1995; 10:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/7\">",
"      Jackson JL, Passamonti M, Kroenke K. Outcome and impact of mental disorders in primary care at 5 years. Psychosom Med 2007; 69:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/8\">",
"      Judd LL, Paulus MP, Wells KB, Rapaport MH. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry 1996; 153:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/9\">",
"      Rucci P, Gherardi S, Tansella M, et al. Subthreshold psychiatric disorders in primary care: prevalence and associated characteristics. J Affect Disord 2003; 76:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/10\">",
"      Lyness JM, King DA, Cox C, et al. The importance of subsyndromal depression in older primary care patients: prevalence and associated functional disability. J Am Geriatr Soc 1999; 47:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/11\">",
"      Olfson M, Broadhead WE, Weissman MM, et al. Subthreshold psychiatric symptoms in a primary care group practice. Arch Gen Psychiatry 1996; 53:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/12\">",
"      Cuijpers P, Smit F, Oostenbrink J, et al. Economic costs of minor depression: a population-based study. Acta Psychiatr Scand 2007; 115:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/13\">",
"      Pincus HA, Davis WW, McQueen LE. 'Subthreshold' mental disorders. A review and synthesis of studies on minor depression and other 'brand names'. Br J Psychiatry 1999; 174:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/14\">",
"      Sherbourne CD, Wells KB, Hays RD, et al. Subthreshold depression and depressive disorder: clinical characteristics of general medical and mental health specialty outpatients. Am J Psychiatry 1994; 151:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/15\">",
"      Rodr&iacute;guez MR, Nuevo R, Chatterji S, Ayuso-Mateos JL. Definitions and factors associated with subthreshold depressive conditions: a systematic review. BMC Psychiatry 2012; 12:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/16\">",
"      Pietrzak RH, Kinley J, Afifi TO, et al. Subsyndromal depression in the United States: prevalence, course, and risk for incident psychiatric outcomes. Psychol Med 2012; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/17\">",
"      Barrett JE, Williams JW Jr, Oxman TE, et al. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. J Fam Pract 2001; 50:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/18\">",
"      Judd LL, Rapaport MH, Yonkers KA, et al. Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. Am J Psychiatry 2004; 161:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/19\">",
"      Rapaport MH, Judd LL, Schettler PJ, et al. A descriptive analysis of minor depression. Am J Psychiatry 2002; 159:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/20\">",
"      Backenstrass M, Frank A, Joest K, et al. A comparative study of nonspecific depressive symptoms and minor depression regarding functional impairment and associated characteristics in primary care. Compr Psychiatry 2006; 47:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/21\">",
"      Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA 1990; 264:2524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/22\">",
"      Newman SC, Bland RC. A population-based family study of minor depression. Depress Anxiety 2009; 26:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/23\">",
"      Hayakawa YK, Sasaki H, Takao H, et al. Structural brain abnormalities in women with subclinical depression, as revealed by voxel-based morphometry and diffusion tensor imaging. J Affect Disord 2013; 144:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/24\">",
"      Boes AD, McCormick LM, Coryell WH, Nopoulos P. Rostral anterior cingulate cortex volume correlates with depressed mood in normal healthy children. Biol Psychiatry 2008; 63:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/25\">",
"      Schlaak JF, Trippler M, Hoyo-Becerra C, et al. Selective hyper-responsiveness of the interferon system in major depressive disorders and depression induced by interferon therapy. PLoS One 2012; 7:e38668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/26\">",
"      Harrison-Woolrych M, Ashton J. Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand. Drug Saf 2011; 34:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/27\">",
"      Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. Am J Psychiatry 2012; 169:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/28\">",
"      Kroenke K, Spitzer RL, Williams JB, et al. Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Arch Fam Med 1994; 3:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/29\">",
"      Katon W, Sullivan M, Walker E. Medical symptoms without identified pathology: relationship to psychiatric disorders, childhood and adult trauma, and personality traits. Ann Intern Med 2001; 134:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/30\">",
"      Crum RM, Cooper-Patrick L, Ford DE. Depressive symptoms among general medical patients: prevalence and one-year outcome. Psychosom Med 1994; 56:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/31\">",
"      Fekadu A, O'Donovan MC, Alem A, et al. Validity of the concept of minor depression in a developing country setting. J Nerv Ment Dis 2008; 196:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/32\">",
"      Preisig M, Merikangas KR, Angst J. Clinical significance and comorbidity of subthreshold depression and anxiety in the community. Acta Psychiatr Scand 2001; 104:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/33\">",
"      Johnson J, Weissman MM, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA 1992; 267:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/34\">",
"      Fogel J, Eaton WW, Ford DE. Minor depression as a predictor of the first onset of major depressive disorder over a 15-year follow-up. Acta Psychiatr Scand 2006; 113:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/35\">",
"      Howland RH, Schettler PJ, Rapaport MH, et al. Clinical features and functioning of patients with minor depression. Psychother Psychosom 2008; 77:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/36\">",
"      Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998; 55:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/37\">",
"      Harris M, Glozier N, Ratnavadivel R, Grunstein RR. Obstructive sleep apnea and depression. Sleep Med Rev 2009; 13:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/38\">",
"      Abebe DS, Lien L, Torgersen L, von Soest T. Binge eating, purging and non-purging compensatory behaviours decrease from adolescence to adulthood: A population-based, longitudinal study. BMC Public Health 2012; 12:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/39\">",
"      Ali S, Stone MA, Peters JL, et al. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med 2006; 23:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/40\">",
"      Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989; 149:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/41\">",
"      Margaretten M, Julian L, Katz P, Yelin E. Depression in patients with rheumatoid arthritis: description, causes and mechanisms. Int J Clin Rheumtol 2011; 6:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/42\">",
"      Meszaros ZS, Perl A, Faraone SV. Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J Clin Psychiatry 2012; 73:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/43\">",
"      Benedetti F, Bernasconi A, Pontiggia A. Depression and neurological disorders. Curr Opin Psychiatry 2006; 19:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/44\">",
"      Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 2003; 54:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/45\">",
"      Wassertheil-Smoller S, Shumaker S, Ockene J, et al. Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI). Arch Intern Med 2004; 164:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/46\">",
"      Katon W, Richardson L, Russo J, et al. Depressive symptoms in adolescence: the association with multiple health risk behaviors. Gen Hosp Psychiatry 2010; 32:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/47\">",
"      Carroll BJ, Cassidy F, Naftolowitz D, et al. Pathophysiology of hypercortisolism in depression. Acta Psychiatr Scand Suppl 2007; :90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/48\">",
"      Stewart JC, Rand KL, Muldoon MF, Kamarck TW. A prospective evaluation of the directionality of the depression-inflammation relationship. Brain Behav Immun 2009; 23:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/49\">",
"      Forsell Y. A three-year follow-up of major depression, dysthymia, minor depression and subsyndromal depression: results from a population-based study. Depress Anxiety 2007; 24:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/50\">",
"      Cuijpers P, Smit F. Subthreshold depression as a risk indicator for major depressive disorder: a systematic review of prospective studies. Acta Psychiatr Scand 2004; 109:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/51\">",
"      Johnson JG, Cohen P, Kasen S. Minor depression during adolescence and mental health outcomes during adulthood. Br J Psychiatry 2009; 195:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/52\">",
"      Work Group on Psychiatric Evaluation, American Psychiatric Association Steering Committee on Practice Guidlines. Psychiatric evaluation of adults. Second edition. American Psychiatric Association. Am J Psychiatry 2006; 163:3.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Practice Guideline for the Psychiatric Evaluation of Adults, Second Edition, 2006. file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on July 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26025/abstract/54\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.",
"     </a>",
"    </li>",
"    <li>",
"     The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. file://www.who.int/classifications/icd/en/bluebook.pdf (Accessed on June 08, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83264 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_26_26025=[""].join("\n");
var outline_f25_26_26025=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H796042097\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H796041971\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H796041978\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H796041985\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1839384\">",
"      General population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1839391\">",
"      Clinical settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5854257\">",
"      Sociodemographic correlates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H796041992\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1839455\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26204824\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86895891\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20072886\">",
"      COMORBIDITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26204853\">",
"      Psychiatric comorbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26205068\">",
"      General medical comorbidity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H796041999\">",
"      COURSE OF ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26204572\">",
"      ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H866458\">",
"      Suicide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26204648\">",
"      Screening tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1839470\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1839404\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H796042097\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/83264\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/83264|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/1/34843\" title=\"table 1\">",
"      Medications that may cause depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/23/8573\" title=\"table 2\">",
"      Research criteria for minor depressive disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/12/14541\" title=\"table 3\">",
"      PHQ-9 questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17756\" title=\"table 4\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/7/4221\" title=\"table 5\">",
"      Differential of chronic fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/41/42651\" title=\"table 6\">",
"      Symptoms and signs of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/25/43419\" title=\"table 7\">",
"      Characteristics of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/31/1535\" title=\"table 8\">",
"      Classification criteria for SLE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=related_link\">",
"      Ambulatory alcohol detoxification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2936?source=related_link\">",
"      Clinical management of substance dependence across the continuum of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=related_link\">",
"      Diagnosis of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31190?source=related_link\">",
"      Grief and bereavement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=related_link\">",
"      Overview of psychosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38201?source=related_link\">",
"      Unipolar depression in adults: Prognosis and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35015?source=related_link\">",
"      Unipolar minor depression in adults: Management and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4745?source=related_link\">",
"      Using scales to monitor symptoms and treatment of depression (measurement based care)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_26_26026="Diagnostic approach to community-acquired pneumonia in adults";
var content_f25_26_26026=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic approach to community-acquired pneumonia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/26/26026/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/26/26026/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/26/26026/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/26/26026/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/26/26026/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/26/26026/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/26/26026/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-acquired pneumonia (CAP) is defined as an acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the community, as distinguished from hospital-acquired (nosocomial) pneumonia. A third category of pneumonia, designated \"healthcare-associated pneumonia,\" is acquired in other healthcare facilities such as nursing homes, dialysis centers, and outpatient clinics or within 90 days of discharge from an acute or chronic care facility [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=see_link\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CAP is a common and potentially serious illness. It is associated with considerable morbidity and mortality, particularly in elderly patients and those with significant comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1801?source=see_link\">",
"     \"Prognosis of community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic approach to CAP in immunocompetent adults will be reviewed here. A variety of other important issues related to CAP are discussed separately. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The epidemiology and microbiology of CAP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link\">",
"       \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of sputum cultures for the evaluation of bacterial pneumonia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17591?source=see_link\">",
"       \"Sputum cultures for the evaluation of bacterial pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment recommendations for CAP in patients treated in the outpatient setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment recommendations for CAP in patients requiring hospitalization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The evidence for efficacy of different antibiotic medications in the empiric treatment of CAP and issues related to drug resistance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=see_link\">",
"       \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumonia in special populations, such as aspiration pneumonia and immunocompromised patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=see_link\">",
"       \"Aspiration pneumonia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=see_link\">",
"       \"Pulmonary infections in immunocompromised patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the patient with community-acquired pneumonia (CAP) begins with the clinical evaluation followed by chest radiograph with or without microbiologic testing. A systematic review highlighted the lack of sensitivity of the clinical criteria for an accurate diagnosis of CAP; even a combination of symptoms (cough) and signs (fever, tachycardia, and crackles) did not have a sensitivity above 50 percent when using chest x-ray as the standard [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common clinical features of CAP include cough, fever, pleuritic chest pain, dyspnea and sputum production. Mucopurulent sputum production is most frequently found in association with bacterial pneumonia, while scant or watery sputum production is more suggestive of an atypical pathogen. Although there are classic descriptions of certain types of sputum production and particular pathogens (eg, pneumococcal pneumonia and rust-colored sputum), these clinical descriptions do not help in clinical decision-making regarding treatment because they are rarely seen.",
"   </p>",
"   <p>",
"    Other common features are gastrointestinal symptoms (nausea, vomiting, diarrhea), and mental status changes. Chest pain occurs in 30 percent of cases, chills in 40 to 50 percent, and rigors in 15 percent. Because of the rapid onset of symptoms, most individuals seek medical care within the first few days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On physical examination, approximately 80 percent are febrile, although this finding is frequently absent in older patients and temperature may be deceptively low in the morning. A respiratory rate above 24",
"    <span class=\"nowrap\">",
"     breaths/minute",
"    </span>",
"    is noted in 45 to 70 percent of patients and may be the most sensitive sign in elderly patients; tachycardia is also common. Chest examination reveals audible rales in most patients, while approximately one-third have evidence of consolidation. However, no clear constellation of symptoms and signs has been found to accurately predict whether or not the patient has pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major blood test abnormality is leukocytosis (typically between 15,000 and 30,000 per mm",
"    <sup>",
"     3",
"    </sup>",
"    ) with a leftward shift. Leukopenia can occur, and generally connotes a poor prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RADIOLOGIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of an infiltrate on plain chest radiograph is considered the gold standard for diagnosing pneumonia when clinical and microbiologic features are supportive. A chest radiograph should be obtained in patients with suspected pneumonia when possible; a demonstrable infiltrate by chest radiograph or other imaging technique is required for the diagnosis of pneumonia, according to the 2007 consensus guidelines from the Infectious Diseases Society of America and the American Thoracic Society",
"    <span class=\"nowrap\">",
"     (IDSA/ATS)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/2\">",
"     2",
"    </a>",
"    ]. Recommendations are less clear in the patient with what appears to be a viral infection with nasal congestion and cough; one approach in these cases is to obtain a chest x-ray when there is an abnormal vital sign with particular emphasis on a respiratory rate &gt;20",
"    <span class=\"nowrap\">",
"     breaths/min",
"    </span>",
"    or a fever. This recommendation is relatively insensitive in elderly patients.",
"   </p>",
"   <p>",
"    The radiographic appearance of community-acquired pneumonia (CAP) may include lobar consolidation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65658 \" href=\"UTD.htm?33/26/34223\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64692 \" href=\"UTD.htm?1/51/1840\">",
"     image 2",
"    </a>",
"    ), interstitial infiltrates (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51752 \" href=\"UTD.htm?9/31/9712\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62313 \" href=\"UTD.htm?37/15/38134\">",
"     image 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61559 \" href=\"UTD.htm?24/0/24580\">",
"     image 5",
"    </a>",
"    ),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cavitation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53664 \" href=\"UTD.htm?27/28/28096\">",
"     image 6",
"    </a>",
"    ). It has been taught that lobar consolidation is due to the \"typical\" bacteria and interstitial infiltrates are due to Pneumocystis jirovecii (formerly P. carinii) and viruses. However, radiologists cannot reliably differentiate bacterial from nonbacterial pneumonia on the basis of the radiographic appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. There is also substantial interobserver variation in the interpretation of chest x-rays in patients with possible pneumonia between different radiologists [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/7,8\">",
"     7,8",
"    </a>",
"    ] and between emergency room physicians and radiologists [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/9\">",
"     9",
"    </a>",
"    ]. It is also clear that high-resolution computed tomography (CT) is superior to chest radiography in detecting lesions and defining anatomical changes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Nevertheless, chest x-ray (PA and lateral) is generally adequate for clinical care of most patients with CAP.",
"   </p>",
"   <p>",
"    If the clinical evaluation does not support pneumonia in a patient with an abnormal chest x-ray, other causes for the radiographic abnormalities must be considered, such as malignancy, hemorrhage, pulmonary edema, pulmonary embolism, and inflammation secondary to noninfectious causes. On the other hand, if the clinical syndrome favors pneumonia but the radiograph is negative, the radiograph may represent a false negative result. In some cases this can be clarified with a CT scan, which, as noted above, has higher sensitivity and accuracy than chest radiographs for detecting CAP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are case reports and animal experiments favoring the hypothesis that volume depletion may produce an initially negative radiograph, which \"blossoms\" into infiltrates following rehydration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/12\">",
"     12",
"    </a>",
"    ]. In support of this hypothesis, one population-based cohort study of suspected CAP found that seven percent of patients with negative initial radiographs developed changes consistent with CAP on repeat chest radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For hospitalized patients with suspected pneumonia and a negative chest radiograph, the 2007",
"    <span class=\"nowrap\">",
"     IDSA/ATS",
"    </span>",
"    consensus guidelines consider it reasonable to initiate empiric presumptive antibiotic therapy and repeat the chest radiograph in 24 to 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/2\">",
"     2",
"    </a>",
"    ]. The basis for this recommendation is from the classic studies of pneumococcal pneumonia, which found that the absence of infiltrate at 24 hours after onset of symptoms indicated the diagnosis needed to be questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/14\">",
"     14",
"    </a>",
"    ]. Alternatively, a CT scan could be performed in patients with a negative chest radiograph when there is a high clinical suspicion for pneumonia. CT scan, especially high resolution CT (HRCT), is more sensitive than plain films for the evaluation of interstitial disease, bilateral disease, cavitation, empyema, and hilar adenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/10,15\">",
"     10,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT scanning is not generally recommended for routine use because the data for its use in CAP are limited, the cost is high, and there is no evidence that it improves outcome. Thus, a chest radiograph is the preferred method for initial imaging, with CT scan or magnetic resonance imaging (MRI) reserved for further anatomical definition (eg, detecting cavitation, adenopathy, or mass lesions).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTING FOR MICROBIAL ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is agreement that treatment is best when it is pathogen-directed, but there is little consensus on the practicality of achieving this goal due to controversies in the value of diagnostic tests.",
"   </p>",
"   <p>",
"    The 2007",
"    <span class=\"nowrap\">",
"     IDSA/ATS",
"    </span>",
"    consensus guidelines recommend diagnostic testing for a specific organism when, based on clinical or epidemiologic data, pathogens which would not respond to usual empiric antibiotic regimens are suspected (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Critical microbes'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/2\">",
"     2",
"    </a>",
"    ]. These guidelines otherwise support the following testing strategy, based on patient characteristics and severity of illness:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For outpatients with community-acquired pneumonia (CAP), routine diagnostic tests are optional.",
"     </li>",
"     <li>",
"      Hospitalized patients with specific indications should have blood cultures and sputum Gram stain and culture",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other tests as outlined in the following Table (",
"      <a class=\"graphic graphic_table graphicRef77432 \" href=\"UTD.htm?4/63/5117\">",
"       table 1",
"      </a>",
"      ); some experts consider diagnostic tests to be optional for hospitalized patients without severe CAP. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hospitalized patients'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with severe CAP requiring ICU admission should have blood cultures, Legionella and pneumococcus urinary antigen tests, and sputum culture (either expectorated or endotracheal aspirate).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Critical microbes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some microbes are critical to detect because they represent important epidemiologic challenges",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serious conditions that require treatment different from standard empiric regimens. These organisms include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Legionella species",
"     </li>",
"     <li>",
"      Influenza A and B, including avian influenza",
"     </li>",
"     <li>",
"      Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)",
"     </li>",
"     <li>",
"      Agents of bioterrorism",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Outpatients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for a microbial diagnosis is usually not performed in outpatients because empiric treatment is almost always successful. In one study of over 700 ambulatory patients treated for CAP, empiric antibiotics (a macrolide or fluoroquinolone in &gt;95 percent) were almost universally effective; only 1 percent required hospitalization due to failure of the outpatient regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2007",
"    <span class=\"nowrap\">",
"     IDSA/ATS",
"    </span>",
"    consensus guidelines suggest that routine tests to identify an etiology for CAP are optional for patients who do not require hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/2\">",
"     2",
"    </a>",
"    ]. An exception is in clinical or epidemiologic settings suggesting a critical microbe is the etiologic agent, in which tests for a microbial diagnosis are important. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Critical microbes'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17591?source=see_link&amp;anchor=H6#H6\">",
"     \"Sputum cultures for the evaluation of bacterial pneumonia\", section on 'Community-acquired pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hospitalized patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most hospitalized patients with CAP in the US are treated empirically with no etiologic diagnosis. A review of the experience of Medicare for 17,340 patients hospitalized for CAP in 2009 showed a microbial diagnosis was made in only 7.6 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/17\">",
"     17",
"    </a>",
"    ]. Several reasons for this include the distancing of the laboratory from the site of care; the Clinical Laboratory Improvement Amendments (CLIA), a ruling that rid hospitals of housestaff labs in 1988; a perception that the quality of microbiology as applied to sputum Gram stain and culture was variably, but generally, poor; the Medicare Performance Indicator policy that required administration of antibiotics within 6 hours of registration in emergency rooms; and a randomized trial showing that medical care outcomes were as good with empiric decisions based on guidelines as they were with pathogen-directed antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/18\">",
"     18",
"    </a>",
"    ]. Despite these observations and realities, there is interest in increasing the acquisition of microbiologic studies in CAP patients along with increased emphasis on better quality in the traditional tests and use of newer molecular techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/19\">",
"     19",
"    </a>",
"    ]. The emphasis on pathogen-directed treatment is motivated by a desire to reduce unnecessary complications (including C. difficile infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/20\">",
"     20",
"    </a>",
"    ]), to limit antibiotic overuse, to reduce resistance, and to improve care [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective study published in 2005 evaluated the diagnostic yield of traditional microbiologic tests in 262 hospitalized patients with CAP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/21\">",
"     21",
"    </a>",
"    ]. Clinical samples included sputum for Gram staining, culture, and detection of pneumococcal antigen; blood for culture and serologic tests; urine for Legionella and pneumococcal antigens; and specimens obtained by bronchoscopy. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pathogen was identified in 158 (60 percent) patients, with S. pneumoniae identified most commonly, accounting for 97 of 158 (61 percent) identified pathogens.",
"     </li>",
"     <li>",
"      Adequate sputum samples were obtained in only 44 patients (17 percent); Gram stain was diagnostic and confirmed by a positive sputum culture in 36 of the 44 patients (82 percent).",
"     </li>",
"     <li>",
"      Urinary pneumococcal antigen test was positive in 52 of the 97 (54 percent) patients with pneumococcal pneumonia.",
"     </li>",
"     <li>",
"      Blood cultures were positive in 40 of 254 (16 percent) patients.",
"     </li>",
"     <li>",
"      Bronchoscopy provided additive diagnostic value in 18 of 37 patients (49 percent) who did not expectorate sputum and in 14 of 27 patients (52 percent) who failed treatment within 72 hours after admission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is substantial interest and progress in the development of molecular methods to detect multiple pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Potential advantages are speed and enhanced sensitivity and specificity. This technology is now available for detecting 16 viral pathogens, Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In a prospective study of 184 adults with CAP, investigators used a comprehensive battery of tests using blood cultures, urinary antigen tests, and respiratory tract specimens for conventional culture plus polymerase chain reaction (PCR) for respiratory viruses and atypical agents (",
"    <a class=\"graphic graphic_figure graphicRef54365 \" href=\"UTD.htm?38/29/39390\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/24\">",
"     24",
"    </a>",
"    ]. For S. pneumoniae and H. influenzae, they used quantitative PCR to avoid the detection of colonizing flora. A likely pathogen was detected in 78 percent of cases and in 89 percent among patients with complete sampling. S. pneumoniae was the most common pathogen (38 percent), and PCR provided the highest yield for its detection. Respiratory viruses were found in 29 percent of cases, and many had bacterial superinfection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Blood cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretreatment blood cultures are positive for a pathogen in 7 to 16 percent of hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/21,25-27\">",
"     21,25-27",
"    </a>",
"    ]. Streptococcus pneumoniae accounts for two-thirds of the positive blood cultures.",
"   </p>",
"   <p>",
"    Blood cultures are commonly advocated in hospitalized patients with CAP because [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When positive for a likely pathogen, the microbial diagnosis is established.",
"     </li>",
"     <li>",
"      This is the only diagnostic test done, in most cases, and is the major source of microbiologic data for many hospitals.",
"     </li>",
"     <li>",
"      The isolates identified serve as an important resource for tracking resistance patterns of S. pneumoniae (eg, the Centers for Disease Control and Prevention [CDC] surveillance network is highly dependent on blood culture data [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/29\">",
"       29",
"      </a>",
"      ]). These are the data used for evaluating efficacy of current S. pneumoniae vaccines and the serotypes needed for inclusion in future vaccines [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/30-32\">",
"       30-32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/37/601?source=see_link&amp;anchor=H9889776#H9889776\">",
"       \"Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States\", section on 'Invasive disease caused by non-vaccine serotypes'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Counter arguments for not obtaining these tests are that [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The blood culture positivity rate is relatively low.",
"     </li>",
"     <li>",
"      There is a high rate of false positive blood cultures (10 percent in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/34\">",
"       34",
"      </a>",
"      ]). Contaminants may actually prolong hospital stays due to a perceived need for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      to treat S. aureus, when the laboratory calls to report gram-positive cocci, which are actually coagulase-negative staphylococci that are not yet identified.",
"     </li>",
"     <li>",
"      Positive cultures rarely lead to modification or narrowing of antibiotic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one study, variables associated with bacteremia included absence of prior antibiotic use, chronic liver disease, pleuritic pain, tachycardia (&gt;125 beats per minute), tachypnea (&gt;30 breaths per minute), and systolic hypotension (&lt;90 mm Hg) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies have suggested that sicker patients (as judged by the pneumonia severity index, PSI) are more likely to have positive blood cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/25\">",
"     25",
"    </a>",
"    ], although this has not been observed in other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/21\">",
"     21",
"    </a>",
"    ]. The 2007",
"    <span class=\"nowrap\">",
"     IDSA/ATS",
"    </span>",
"    consensus guidelines recommend blood cultures for hospitalized patients with specific indications, including all patients who require admission to the ICU for CAP, and consider them optional for other patients (",
"    <a class=\"graphic graphic_table graphicRef77432 \" href=\"UTD.htm?4/63/5117\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Sputum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expectorated sputum can be submitted for Gram stain and culture, but the utility of these tests is subject to substantial controversy due in part to variations in the quality of service and distance of the clinical microbiology laboratory, the apparent success of empiric treatment, and the need to initiate antibiotic treatment while in the emergency room or clinic. Thus, the rate of pathogen detection varies in studies, some with a pathogen detection rate of &lt;10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/36,37\">",
"     36,37",
"    </a>",
"    ] and others with yields of 54 to 86 percent, particularly in patients with bacteremic pneumococcal pneumonia or when invasive procedures were used to obtain samples [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/28,38,39\">",
"     28,38,39",
"    </a>",
"    ]. A review of Medicare data from 33,000 patients hospitalized for CAP in the United States showed that only 7.6 percent had a pathogen detected [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2007",
"    <span class=\"nowrap\">",
"     IDSA/ATS",
"    </span>",
"    consensus guidelines recognize the limitations of sputum Gram stain and culture [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/2\">",
"     2",
"    </a>",
"    ]. The guidelines recommend that pretreatment sputum Gram stain and culture of expectorated sputum be performed only if a good quality sputum can be obtained, with appropriate measures in place for collection, transport and processing to assure quality performance. Under these circumstances, expectorated sputum specimens are recommended for hospitalized patients with any of the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intensive care unit admission",
"     </li>",
"     <li>",
"      Failure of antibiotic therapy (either outpatients or hospitalized patients) although the clinician must be aware that post-treatment specimens are notorious for colonization by resistant bacteria",
"     </li>",
"     <li>",
"      Cavitary lesions, although anaerobic bacteria, the usual cause of primary lung abscess, would require an uncontaminated sputum sample for detection; this requires culture of empyema fluid, a transtracheal aspirate, transthoracic aspirate or (possibly) a quantitative bronchoscopic aspirate.",
"     </li>",
"     <li>",
"      Active alcohol abuse",
"     </li>",
"     <li>",
"      Severe obstructive or structural lung disease",
"     </li>",
"     <li>",
"      Immunocompromised host",
"     </li>",
"     <li>",
"      Pleural effusion",
"     </li>",
"     <li>",
"      Likelihood of an epidemiologically important pathogen such as Legionella spp, influenza, or an agent of bioterrorism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Standards of quality control for sputum culture for bacterial pathogens have been proposed and include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The specimen should be a deep cough specimen obtained prior to antibiotics.",
"     </li>",
"     <li>",
"      Cultures should be performed rapidly after collection, preferably within two hours; the alternative for rapid plating of the sample is to retain the specimen at 4&ordm;C if the delay is more than two hours [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A \"good\" sputum sample is one with polymorphonuclear leukocytes (PMNs) but a low or absent number of squamous epithelial cells (SECs) on Gram stain. The best correlation of the cytologic screening by Gram stain of sputum with a transtracheal aspiration sample was achieved with the criterion of &lt;25 SECs per low power field (LPF) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/41\">",
"       41",
"      </a>",
"      ]. It should be noted that these criteria do not apply to cultures for Legionella or mycobacteria [",
"      <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sensitivity and specificity of the sputum Gram stain vary substantially in different settings. A meta-analysis evaluated 12 studies of the sensitivity and specificity of the sputum Gram stain in CAP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/43\">",
"     43",
"    </a>",
"    ]. The sensitivity of Gram stain compared to culture ranged from 15 to 100 percent and specificity ranged from 11 to 100 percent.",
"   </p>",
"   <p>",
"    Culture results should be interpreted based upon the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Quantitation of growth (heavy, moderate, or light)",
"     </li>",
"     <li>",
"      Clinical correlation",
"     </li>",
"     <li>",
"      Correlation with the Gram stain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    True pathogens should be present in moderate or heavy amounts by Gram stain and culture. However, some agents are regarded as significant regardless of concentration, including Legionella spp, Bacillus anthracis, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Chlamydophila psittaci; these respiratory pathogens are virtually never colonizers, but always represent disease.",
"   </p>",
"   <p>",
"    Antibiotics may alter the yield of any subsequent culture of respiratory secretions. Specimens collected after antibiotics are given are more likely to grow S. aureus or gram-negative bacilli (GNB), which usually represent early airway contaminants.",
"   </p>",
"   <p>",
"    When S. pneumoniae and Haemophilus influenzae are the etiologic agent, false negative cultures are common because of their fastidious growth requirements and the lack of selective media. By contrast, S. aureus and GNB are relatively rare pulmonary pathogens that are easily grown in respiratory secretions because they are hardy and easily recognized by growth on selective media. The failure to grow these organisms is strong evidence against their presence and, when grown, they often represent contaminants.",
"   </p>",
"   <p>",
"    The preferred tests for Legionella are culture on selective media and the urinary antigen assay. A travel history should be obtained in patients presenting with CAP, and Legionella testing ordered for patients who have traveled in the two weeks before symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/2\">",
"     2",
"    </a>",
"    ]. The risk of Legionella infection is especially associated with contaminated water in hotels, although outbreaks have occurred in diverse settings including hospitals, cruise ships, and industrial plants. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Urinary antigen'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38199?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations and diagnosis of Legionella infection\", section on 'Specific laboratory diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32680?source=see_link\">",
"     \"Epidemiology and pathogenesis of Legionella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Urinary antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative or complementary methods to detect S. pneumoniae and Legionella are urinary antigen assays. There are several advantages and disadvantages to urine antigen testing compared with culture.",
"   </p>",
"   <p>",
"    The advantages are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most studies show these urinary antigen tests are more sensitive and specific than Gram stain and culture of sputum as commonly done by most labs.",
"     </li>",
"     <li>",
"      Urine specimens are usually available in the 30 to 40 percent of patients who cannot supply expectorated sputum.",
"     </li>",
"     <li>",
"      Results of urine antigen testing are immediately available.",
"     </li>",
"     <li>",
"      The test retains validity even after the initiation of antibiotic therapy.",
"     </li>",
"     <li>",
"      The test has high sensitivity compared with blood cultures and sputum studies and high specificity.",
"     </li>",
"     <li>",
"      The urinary antigen tests for Legionella and S. pneumoniae are FDA-cleared and provide results in minutes; the reagents are commercially available, and they require no equipment. They are not CLIA-waived, meaning they must be done by a laboratory technician.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disadvantages of the urine antigen assay for the diagnosis of pneumococcus include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sensitivity and specificity may be less in patients without bacteremia.",
"     </li>",
"     <li>",
"      There is no microbial pathogen available for antibiotic sensitivity testing.",
"     </li>",
"     <li>",
"      These tests require a licensed technician and cannot be done by the provider despite their simplicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A disadvantage of the urine antigen assay for the diagnosis of Legionella is that it is only useful for the diagnosis of L. pneumophila group 1 infection. Nevertheless, this serogroup accounts for 80 percent of Legionnaires' disease acquired in the community and in hotels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Nosocomial Legionella infections often involve other serotypes, so sensitivity is decreased.",
"   </p>",
"   <p>",
"    A prospective trial evaluated the sensitivity and specificity of the pneumococcal urinary antigen test in 107 patients with bacteremic pneumococcal infection compared with 106 patients with septicemia caused by other organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/46\">",
"     46",
"    </a>",
"    ]. Antigen was detected in 88 of 107 pneumococcal bacteremic patients (82 percent) compared with 3 of 106 patients with bacteremia due to other pathogens (3 percent), for a sensitivity and specificity of 82 and 97 percent, respectively. It is important to note that these findings were in patients with bacteremic pneumococcal pneumonia and may not reflect what occurs in patients without bacteremia.",
"   </p>",
"   <p>",
"    In a subsequent prospective study that included 171 adults hospitalized with CAP caused by S. pneumoniae, the majority of whom did not have S. pneumoniae isolated from blood cultures, the sensitivity of the pneumococcal urinary antigen was 71 percent and the specificity was 96 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/47\">",
"     47",
"    </a>",
"    ]. Among patients with a definite diagnosis of pneumococcal CAP, the sensitivity of urinary antigen testing was 78 percent compared with 57 percent in those with a probable diagnosis. A definite diagnosis was defined as S. pneumoniae isolated from a blood culture or pleural fluid culture, or detected by PCR from pleural fluid, whereas a probable diagnosis required S. pneumoniae to be the predominant organism in a good quality sputum sample with an accompanying positive Gram stain. Pneumococcal CAP was diagnosed exclusively by the urinary antigen test in 75 cases (44 percent). The results of the urinary antigen test led clinicians to reduce the spectrum of antibiotics in 41 of 474 patients with CAP (9 percent). This study suggests that although the sensitivity of the pneumococcal urinary antigen test is lower in patients who are not bacteremic, the presence of a positive urinary antigen test in a non-bacteremic patient can be helpful for tailoring therapy.",
"   </p>",
"   <p>",
"    According to the 2007 Infectious Diseases Society of America and the American Thoracic Society",
"    <span class=\"nowrap\">",
"     (IDSA/ATS)",
"    </span>",
"    consensus guidelines on CAP, the pneumococcal urinary antigen assay may augment the standard diagnostic methods of blood culture and sputum Gram stain and culture, with the potential advantage of rapid results similar to those for sputum Gram stain [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/2\">",
"     2",
"    </a>",
"    ]. It is of particular value when antibiotic therapy has already been initiated, prior to obtaining a sputum sample; specimens may remain positive three days after antibiotic initiation. A disadvantage compared to culture is the inability to test antibiotic sensitivity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13386?source=see_link\">",
"     \"Pneumococcal pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The standard tests to diagnose Legionella spp infection in most clinical laboratories are culture on selective media and the urinary antigen assay (",
"    <a class=\"graphic graphic_table graphicRef69022 \" href=\"UTD.htm?16/40/17035\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/44,48,49\">",
"     44,48,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38199?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Legionella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like the urinary antigen assay, polymerase chain reaction (PCR) may help improve accuracy of the microbiologic diagnosis for patients with CAP with a rapid turn-around time [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/24,50,51\">",
"     24,50,51",
"    </a>",
"    ]. One limitation of PCR when used on respiratory specimens, including bronchoscopic samples, is that specimens are contaminated by the upper airway flora [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Thus, a quantitative PCR assay is necessary, and the results must be interpreted with the understanding that some of the pathogens isolated may be colonizers of the upper respiratory tract [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/24\">",
"     24",
"    </a>",
"    ]. Another limitation is that these are not point-of-care tests meaning they require a laboratory and laboratory technician. This may present logistical problems in facilities that have outsourced microbiology or have limited coverage",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral pathogens that cause community-acquired pneumonia include influenza, adenovirus, parainfluenza, respiratory syncytial virus, and human metapneumovirus. The diagnosis of these viruses can be made by culture, serology, or through rapid diagnostic testing with enzyme immunoassay (EIA), immunofluorescence, or polymerase chain reaction (PCR). PCR-based diagnostic panels have been developed that can detect multiple respiratory viruses simultaneously and can be performed in two to three hours in hospital laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Using such a panel can aid in the rapid diagnosis of viral pneumonia, which might reduce the unnecessary use of antibacterial agents. Caution is necessary in interpretation since up to 15 percent of healthy persons harbor a respiratory tract virus at any point of time [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/56\">",
"     56",
"    </a>",
"    ]. An exception is influenza since detection of this virus usually indicates infection. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Polymerase chain reaction'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/617?source=see_link\">",
"     \"Parainfluenza viruses in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=see_link\">",
"     \"Respiratory syncytial virus infection: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=see_link\">",
"     \"Human metapneumovirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5528?source=see_link\">",
"     \"Diagnosis of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37513?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis and treatment of adenovirus infection\", section on 'Pneumonia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=see_link&amp;anchor=H39276461#H39276461\">",
"     \"Clinical manifestations of seasonal influenza in adults\", section on 'Duration of shedding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of influenza infection is discussed below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Influenza'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROCALCITONIN AND CRP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biologic markers are sometimes used to try to distinguish between bacterial and non-bacterial causes of pneumonia. The two most promising are procalcitonin (PCT) and C-reactive protein (CRP).",
"   </p>",
"   <p>",
"    Procalcitonin is a peptide precursor of calcitonin that is released by parenchymal cells in response to bacterial toxins, leading to elevated serum levels in patients with bacterial infections; in contrast, procalcitonin is down-regulated in patients with viral infections. Procalcitonin is measured by two commercially available tests, the Kryptor assay and the LUMI assay; the former is preferred due to higher sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Procalcitonin has been studied prospectively to facilitate the decision of whether to use antibacterial agents in patients with pneumonia and when antibiotics can be safely stopped. In two trials, clinicians were strongly recommended not to prescribe antibacterials in patients with a procalcitonin level &lt;0.1",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    but were encouraged to use antibacterials in patients with levels &gt;0.25",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. The analysis suggested the correct decision in 83 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/59\">",
"     59",
"    </a>",
"    ]. Several trials have shown that using procalcitonin results to help determine whether antibiotics are necessary results in lower rates of antibiotic exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/58-60\">",
"     58-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis that used individual patient data from 14 trials of 4221 patients with acute respiratory infections (half of whom had CAP), procalcitonin guidance for antibiotic use was associated with a reduction in antibiotic exposure without an increase in mortality or treatment failure in any clinical setting (eg, outpatient clinic, emergency department) or in patients with any type of acute respiratory infection, including CAP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/61\">",
"     61",
"    </a>",
"    ]. Nevertheless, further trials are necessary to establish the safety of procalcitonin-based treatment algorithms, particularly in critically ill patients.",
"   </p>",
"   <p>",
"    Other studies have shown that procalcitonin levels correlate with the severity of pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. In one small study, procalcitonin levels increased over time in non-survivors but decreased in survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/63\">",
"     63",
"    </a>",
"    ]. Procalcitonin levels also predict bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/64\">",
"     64",
"    </a>",
"    ]. These studies show that procalcitonin levels help to distinguish between bacterial and viral pneumonia, reduce antibacterial use, predict severity based on the magnitude of the result, and may predict survival.",
"   </p>",
"   <p>",
"    The use of procalcitonin for distinguishing between bacterial and viral bronchitis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29289?source=see_link&amp;anchor=H18#H18\">",
"     \"Acute bronchitis in adults\", section on 'Procalcitonin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CRP has shown more limited utility, due in part to the paucity of studies. One study showed a CRP &gt;40",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    had a sensitivity and specificity for bacterial pneumonia of 70 and 90 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/65\">",
"     65",
"    </a>",
"    ]. Another study that included 364 patients with respiratory infection showed a sensitivity of 73 percent and specificity of 65 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/66\">",
"     66",
"    </a>",
"    ]. Another report indicated particularly high CRP levels in patients with pneumococcal pneumonia (mean 178",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/67\">",
"     67",
"    </a>",
"    ]. CRP appears to be less sensitive than procalcitonin for the detection of bacterial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/63\">",
"     63",
"    </a>",
"    ]. Both of these tests need to be interpreted in the context of clinical observations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ORGANISMS OF SPECIAL INTEREST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common etiologic agents of CAP or those that are less common but require more specific therapy are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Streptococcus pneumoniae",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. pneumoniae accounts for about 65 percent of bacteremic pneumonia cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/68\">",
"     68",
"    </a>",
"    ] and is the most common identified pathogen in nearly all studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the pre-antibiotic era, the pneumococcus was identified in 80 percent of all cases of pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/69\">",
"     69",
"    </a>",
"    ]. A meta-analysis evaluated 127 unique study cohorts of CAP etiology and identified the pneumococcus in 73 percent of cases in which any likely pathogen was recovered, but in only 18 percent of the cases studied was any pathogen identified [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13386?source=see_link\">",
"     \"Pneumococcal pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The yield with sputum Gram stain and culture is variable and dependent on the quality of the sputum processing, the experience of the reader, and population studied. Among patients with bacteremic pneumococcal pneumonia the yield with expectorated sputum ranges from &le;50 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/70\">",
"     70",
"    </a>",
"    ] to &ge;80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/28\">",
"     28",
"    </a>",
"    ] in labs with good quality control. Diagnostic ability may be enhanced with the addition of a urine antigen test to sputum culture. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Urinary antigen'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    It is expected that a polymerase chain reaction assay for the detection of S. pneumoniae will be available in the near future, but this will probably require quantitation when using specimens contaminated by the oral flora due to the sensitivity of these methods and the frequency of carriage of pneumococci in the upper airways [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pneumococcal urinary antigen assay is discussed above. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Urinary antigen'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Staphylococcus aureus",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. aureus is an infrequent pulmonary pathogen, but important to detect since strains that bear the genes for the Panton-Valentine leukocidin (PVL) have the potential to cause pulmonary necrosis and sepsis syndromes (usually USA 300 strains that are also methicillin-resistant) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]. S. aureus in these cases is usually recovered from blood and in contrast to S. pneumoniae, is easy to recover from respiratory secretion.",
"   </p>",
"   <p>",
"    Although a PCR assay has been developed that can detect the Panton-Valentine leukocidin genes that are present in the USA 300 strain, it is not available at many hospital and commercial labs. Clues to this clonal strain (USA 300) include the clinical features of a rapidly progressive lung infection in a previously healthy young adult or child that is often accompanied by pulmonary necrosis and shock. The sensitivity profile, due to the mecIV element, is also unique in that it shows resistance to all beta-lactams, but commonly shows susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40758?source=see_link\">",
"     \"Virulence determinants of community acquired methicillin-resistant Staphylococcus aureus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    S. aureus should be suspected in patients with influenza and a bacterial superinfection, especially those with the clinical characteristics of staphylococcal toxic shock syndrome, or the unique features of pneumonia caused by USA 300 strains (eg, pulmonary necrosis, shock, and neutropenia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza is important to recognize because of the need for appropriate infection control in hospitalized patients, for public health reporting purposes, and for rapid treatment with antiviral agents. During influenza outbreaks, most patients can be diagnosed on clinical grounds alone. Rapid point-of-care diagnostic tests are available for detecting influenza. However, these tests have low sensitivity, so a negative result does not rule out influenza infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Real-time reverse-transcriptase PCR is the test of choice to diagnose influenza, when necessary. The need to know the influenza type depends partly on whether multiple influenza strains with different resistance patterns are circulating. For example, the majority of seasonal influenza H1N1 during the 2008 to 2009 season were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    , but almost all isolates of pandemic H1N1 influenza in 2009 to 2010 were susceptible to oseltamivir [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5528?source=see_link\">",
"     \"Diagnosis of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=see_link\">",
"     \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=see_link\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39880?source=see_link\">",
"     \"Antiviral drug resistance among seasonal influenza viruses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For severe and sporadic cases of influenza-like illness, there is more urgency to make a specific diagnosis due to concern for H5N1 (avian influenza) or other emerging strains. In such situations, diagnostic tests such as enzyme immunoassay or PCR for influenza are appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/77\">",
"     77",
"    </a>",
"    ]. Reagents to test for novel influenza strains when they first emerge may be available only in public health laboratories; local hospital laboratory supervisors will know the specimen referral process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5528?source=see_link\">",
"     \"Diagnosis of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22599?source=see_link\">",
"     \"Clinical manifestations and diagnosis of avian influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Viral culture results take approximately two to five days and are mainly used to track which viruses are circulating during a given season. Viral culture is less sensitive that PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/77\">",
"     77",
"    </a>",
"    ]. There needs to be caution in attributing pneumonia to respiratory viruses, since about 15 percent of healthy adults harbor a virus without symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/56\">",
"     56",
"    </a>",
"    ]. An exception is influenza, which is rarely detected in the absence of clinical illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Legionella spp",
"    </span>",
"    &nbsp;&mdash;&nbsp;Legionella is implicated in approximately 2 to 9 percent of CAP cases, depending on the site of care (severity). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Legionella is important to identify because of the potential to cause epidemics (usually in hospitals and hotels) and because Legionella spp infection has a relatively high mortality rate, even with proper treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33015?source=see_link\">",
"     \"Treatment and prevention of Legionella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Chlamydophila (Chlamydia) pneumoniae",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of Chlamydophila (Chlamydia) pneumoniae in adults with CAP has varied in different studies from 0 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/24,80-82\">",
"     24,80-82",
"    </a>",
"    ], although the validity of these data is in question due to problems with diagnostic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. One problem is the use of a serologic test in many studies, which lacks both sensitivity and specificity for C. pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/83\">",
"     83",
"    </a>",
"    ]. In addition, positive serologic results may represent either current or past infection. Some authorities feel the disease is rarely diagnosed because its occurrence is largely limited to outbreaks and some consider the only valid tests to be tissue culture [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/83\">",
"     83",
"    </a>",
"    ] or PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/85\">",
"     85",
"    </a>",
"    ]. In 2012, a multiplex PCR assay was cleared by the US Food and Drug Administration (FDA) for the diagnosis of C. pneumoniae using nasopharyngeal samples [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7270?source=see_link&amp;anchor=H6#H6\">",
"     \"Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mycoplasma pneumoniae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycoplasma pneumoniae has historically been considered a pathogen primarily of children and adolescents, but there are reports of increasingly high rates of infection in adults, especially elderly adults. Diagnostic methods to detect M. pneumoniae infection include culture (which is rarely offered, but generally considered the \"gold standard\"), PCR (not commercially available), and serology with IgM and IgG (the most commonly performed assay) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. In 2012, a multiplex PCR assay was cleared by the FDA for the diagnosis of M. pneumoniae using nasopharyngeal samples [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. The difficulty of using serology for diagnosis is the serologic response is often delayed, so that results may not be available at the time of selection of antimicrobial therapy. The other concerns are the difficulty in showing a correlation between positive results of standard tests and response to therapy in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/90\">",
"     90",
"    </a>",
"    ] and poor correlation when comparing PCR, serology and culture [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/91\">",
"     91",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/5/3162?source=see_link&amp;anchor=H16#H16\">",
"     \"Mycoplasma pneumoniae infection in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Anaerobic bacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaerobic bacteria were well recognized agents of aspiration pneumonia and lung abscess during the period 1970 to 1980 when transtracheal aspiration was a common method to obtain uncontaminated specimens that were valid for anaerobic culture [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. Transtracheal aspiration is no longer performed due to safety concerns. Subsequently there has been interest in the use of quantitative cultures of bronchoscopic aspirates using bronchoalveolar lavage or the protected brush catheter. Although this procedure can be done, there is only one published study documenting the validity of this approach, and strict quality assurance is critical including the admonition to exclude patients who have received antibiotics, avoid",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    with preservative, and expedite processing of cultures due to the fastidious nature of these organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/94\">",
"     94",
"    </a>",
"    ]. Anaerobes should be suspected on clinical grounds when there is aspiration, a pulmonary cavity in an aspiration-prone patient, putrid discharge (sputum or empyema fluid),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    no likely aerobic pathogen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=see_link\">",
"     \"Aspiration pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Bioterrorism agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents that may be used for bioterrorism and can cause a pneumonic syndrome include Bacillus anthracis (inhalational anthrax), Yersinia pestis (pneumonic plague), Francisella tularensis (tularemia), Coxiella burnetii (Q fever), Legionella spp, influenza virus, hantavirus, and ricin (",
"    <a class=\"graphic graphic_table graphicRef56078 \" href=\"UTD.htm?4/10/4268\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/26/26026/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22247?source=see_link\">",
"     \"Identifying and managing casualties of biological terrorism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=see_link\">",
"       \"Patient information: Pneumonia in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=see_link\">",
"       \"Patient information: Pneumonia in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical features and radiographic changes are usually not helpful in identifying the etiologic pathogen of CAP. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Radiologic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of an infiltrate on plain chest radiograph is considered the \"gold standard\" for diagnosing pneumonia when clinical and microbiologic features are supportive. False negative chest radiographs are occasionally attributed to an infection very early in the course (&lt;24 hours), neutropenia, dehydration, and PCP. The only common cause of a false negative radiograph is infection with Pneumocystis carinii pneumonia (PCP, but officially renamed Pneumocystis jirovecii pneumonia). For PCP infection, spiral CT scans are more sensitive. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Radiologic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiologists cannot reliably differentiate bacterial from nonbacterial pneumonia on the basis of the radiographic appearance. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Radiologic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tests for a microbial diagnosis in outpatients with suspected CAP are optional. Not testing is appropriate in most patients since empiric treatment is usually successful. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Outpatients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for performing specific tests in hospitalized patients with CAP are shown in the following Table (",
"      <a class=\"graphic graphic_table graphicRef77432 \" href=\"UTD.htm?4/63/5117\">",
"       table 1",
"      </a>",
"      ). The combination of a good sputum specimen for Gram stain and culture plus urinary antigen testing is likely to be most useful for the rapid diagnosis of CAP, although diagnostic testing is optional for patients without specific indications. Patients hospitalized in the intensive care unit (ICU) should have pretreatment blood cultures, sputum culture and Gram stain, and urine antigen tests. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnostic testing for microbial etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The blood culture positivity rate is relatively low, but when positive for a likely pulmonary pathogen, this establishes the microbial diagnosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Blood cultures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are some pulmonary pathogens that are particularly important to recognize due to their epidemiologic significance",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      their need for treatment strategies that differ from the regimens commonly used by empiric selection. These pathogens include Legionella spp, community-acquired methicillin-resistant Staphylococcus aureus, influenza, and agents of bioterrorism. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Organisms of special interest'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/1\">",
"      Craven DE, Palladino R, McQuillen DP. Healthcare-associated pneumonia in adults: management principles to improve outcomes. Infect Dis Clin North Am 2004; 18:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/2\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/3\">",
"      Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med 2003; 138:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/4\">",
"      Marrie TJ. Community-acquired pneumonia. Clin Infect Dis 1994; 18:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/5\">",
"      Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997; 278:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/6\">",
"      Jartti A, Rauvala E, Kauma H, et al. Chest imaging findings in hospitalized patients with H1N1 influenza. Acta Radiol 2011; 52:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/7\">",
"      Hopstaken RM, Witbraad T, van Engelshoven JM, Dinant GJ. Inter-observer variation in the interpretation of chest radiographs for pneumonia in community-acquired lower respiratory tract infections. Clin Radiol 2004; 59:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/8\">",
"      Albaum MN, Hill LC, Murphy M, et al. Interobserver reliability of the chest radiograph in community-acquired pneumonia. PORT Investigators. Chest 1996; 110:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/9\">",
"      Campbell SG, Murray DD, Hawass A, et al. Agreement between emergency physician diagnosis and radiologist reports in patients discharged from an emergency department with community-acquired pneumonia. Emerg Radiol 2005; 11:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/10\">",
"      Syrj&auml;l&auml; H, Broas M, Suramo I, et al. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 1998; 27:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/11\">",
"      Nyamande K, Lalloo UG, Vawda F. Comparison of plain chest radiography and high-resolution CT in human immunodeficiency virus infected patients with community-acquired pneumonia: a sub-Saharan Africa study. Br J Radiol 2007; 80:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/12\">",
"      Feldman C. Pneumonia in the elderly. Clin Chest Med 1999; 20:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/13\">",
"      Basi SK, Marrie TJ, Huang JQ, Majumdar SR. Patients admitted to hospital with suspected pneumonia and normal chest radiographs: epidemiology, microbiology, and outcomes. Am J Med 2004; 117:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/14\">",
"      Davies D, Hodgson HG, Whitby LEH. A study of pneumococcal pneumonia III: The radiology of pneumonia. Lancet 1935; 1:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/15\">",
"      Wheeler JH, Fishman EK. Computed tomography in the management of chest infections: current status. Clin Infect Dis 1996; 23:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/16\">",
"      Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/17\">",
"      Bartlett JG. Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis 2011; 52 Suppl 4:S296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/18\">",
"      van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005; 60:672.",
"     </a>",
"    </li>",
"    <li>",
"     Gilbert D, Spellberg, Bartlett JG. Recommendations for diagnostic studies in respiratory tract infections (Position paper of the Infectious Diseases Society of America). Clin Infect Dis 2010; [in press].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/20\">",
"      Polgreen PM, Chen YY, Cavanaugh JE, et al. An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia. Infect Control Hosp Epidemiol 2007; 28:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/21\">",
"      van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005; 24:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/22\">",
"      File TM Jr. New diagnostic tests for pneumonia: what is their role in clinical practice? Clin Chest Med 2011; 32:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/23\">",
"      Cho MC, Kim H, An D, et al. Comparison of sputum and nasopharyngeal swab specimens for molecular diagnosis of Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila. Ann Lab Med 2012; 32:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/24\">",
"      Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/25\">",
"      Waterer GW, Wunderink RG. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir Med 2001; 95:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/26\">",
"      Chalasani NP, Valdecanas MA, Gopal AK, et al. Clinical utility of blood cultures in adult patients with community-acquired pneumonia without defined underlying risks. Chest 1995; 108:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/27\">",
"      Falguera M, Trujillano J, Caro S, et al. A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia. Clin Infect Dis 2009; 49:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/28\">",
"      Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2004; 39:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/29\">",
"      Stephens DS, Zughaier SM, Whitney CG, et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 2005; 365:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/30\">",
"      Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008; 57:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/31\">",
"      Moore MR, Whitney CG. Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect? Clin Infect Dis 2008; 46:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/32\">",
"      Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/33\">",
"      Campbell SG, Marrie TJ, Anstey R, et al. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest 2003; 123:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/34\">",
"      Corbo J, Friedman B, Bijur P, Gallagher EJ. Limited usefulness of initial blood cultures in community acquired pneumonia. Emerg Med J 2004; 21:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/35\">",
"      Campbell SG, Marrie TJ, Anstey R, et al. Utility of blood cultures in the management of adults with community acquired pneumonia discharged from the emergency department. Emerg Med J 2003; 20:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/36\">",
"      Lentino JR, Lucks DA. Nonvalue of sputum culture in the management of lower respiratory tract infections. J Clin Microbiol 1987; 25:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/37\">",
"      Ewig S, Schlochtermeier M, G&ouml;ke N, Niederman MS. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Chest 2002; 121:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/38\">",
"      Busk MF, Rosenow EC 3rd, Wilson WR. Invasive procedures in the diagnosis of pneumonia. Semin Respir Infect 1988; 3:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/39\">",
"      Cordero E, Pach&oacute;n J, Rivero A, et al. Usefulness of sputum culture for diagnosis of bacterial pneumonia in HIV-infected patients. Eur J Clin Microbiol Infect Dis 2002; 21:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/40\">",
"      Jefferson H, Dalton HP, Escobar MR, Allison MJ. Transportation delay and the microbiological quality of clinical specimens. Am J Clin Pathol 1975; 64:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/41\">",
"      Geckler RW, McAllister CK, Gremillion DH, Ellenbogen C. Clinical value of paired sputum and transtracheal aspirates in the initial management of pneumonia. Chest 1985; 87:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/42\">",
"      Ingram JG, Plouffe JF. Danger of sputum purulence screens in culture of Legionella species. J Clin Microbiol 1994; 32:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/43\">",
"      Reed WW, Byrd GS, Gates RH Jr, et al. Sputum gram's stain in community-acquired pneumococcal pneumonia. A meta-analysis. West J Med 1996; 165:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/44\">",
"      Helbig JH, Uldum SA, Bernander S, et al. Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-associated, and nosocomial legionnaires' disease. J Clin Microbiol 2003; 41:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/45\">",
"      Yu VL, Plouffe JF, Pastoris MC, et al. Distribution of Legionella species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. J Infect Dis 2002; 186:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/46\">",
"      Smith MD, Derrington P, Evans R, et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol 2003; 41:2810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/47\">",
"      Sord&eacute; R, Falc&oacute; V, Lowak M, et al. Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med 2011; 171:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/48\">",
"      Murdoch DR. Diagnosis of Legionella infection. Clin Infect Dis 2003; 36:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/49\">",
"      Stout JE, Yu VL. Legionellosis. N Engl J Med 1997; 337:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/50\">",
"      Templeton KE, Scheltinga SA, van den Eeden WC, et al. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis 2005; 41:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/51\">",
"      Oosterheert JJ, van Loon AM, Schuurman R, et al. Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection. Clin Infect Dis 2005; 41:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/52\">",
"      Park HK, Lee HJ, Lee HJ, Kim W. Real-time PCR assays for the detection and quantification of Streptococcus pneumoniae. FEMS Microbiol Lett 2010; 310:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/53\">",
"      Resti M, Micheli A, Moriondo M, et al. Comparison of the effect of antibiotic treatment on the possibility of diagnosing invasive pneumococcal disease by culture or molecular methods: a prospective, observational study of children and adolescents with proven pneumococcal infection. Clin Ther 2009; 31:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/54\">",
"      Lieberman D, Shimoni A, Shemer-Avni Y, et al. Respiratory viruses in adults with community-acquired pneumonia. Chest 2010; 138:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/55\">",
"      Caliendo AM. Multiplex PCR and emerging technologies for the detection of respiratory pathogens. Clin Infect Dis 2011; 52 Suppl 4:S326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/56\">",
"      Jartti T, Jartti L, Peltola V, et al. Identification of respiratory viruses in asymptomatic subjects: asymptomatic respiratory viral infections. Pediatr Infect Dis J 2008; 27:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/57\">",
"      Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis 2011; 52 Suppl 4:S346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/58\">",
"      Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/59\">",
"      Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/60\">",
"      Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/61\">",
"      Schuetz P, M&uuml;ller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012; 9:CD007498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/62\">",
"      Masi&aacute; M, Guti&eacute;rrez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005; 128:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/63\">",
"      Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006; 32:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/64\">",
"      M&uuml;ller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010; 138:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/65\">",
"      Flanders SA, Stein J, Shochat G, et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am J Med 2004; 116:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/66\">",
"      Holm A, Nexoe J, Bistrup LA, et al. Aetiology and prediction of pneumonia in lower respiratory tract infection in primary care. Br J Gen Pract 2007; 57:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/67\">",
"      Almirall J, Bol&iacute;bar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004; 125:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/68\">",
"      Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/69\">",
"      Bullowa, JGM. The reliability of sputum typing and its relation to serum therapy. JAMA 1935; 105:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/70\">",
"      Barrett-Connor E. The nonvalue of sputum culture in the diagnosis of pneumococcal pneumonia. Am Rev Respir Dis 1971; 103:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/71\">",
"      Klugman KP, Madhi SA, Albrich WC. Novel approaches to the identification of Streptococcus pneumoniae as the cause of community-acquired pneumonia. Clin Infect Dis 2008; 47 Suppl 3:S202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/72\">",
"      Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/73\">",
"      Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/74\">",
"      Prechter GC, Gerhard AK. Postinfluenza toxic shock syndrome. Chest 1989; 95:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/75\">",
"      Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/76\">",
"      Centers for Disease Control and Prevention (CDC). Performance of rapid influenza diagnostic tests during two school outbreaks of 2009 pandemic influenza A (H1N1) virus infection - Connecticut, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/77\">",
"      Landry ML. Diagnostic tests for influenza infection. Curr Opin Pediatr 2011; 23:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/78\">",
"      Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/79\">",
"      Tamura D, Sugaya N, Ozawa M, et al. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis 2011; 52:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/80\">",
"      Shibli F, Chazan B, Nitzan O, et al. Etiology of community-acquired pneumonia in hospitalized patients in northern Israel. Isr Med Assoc J 2010; 12:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/81\">",
"      Song JH, Oh WS, Kang CI, et al. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents 2008; 31:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/82\">",
"      Cill&oacute;niz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011; 66:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/83\">",
"      Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis 2007; 44:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/84\">",
"      Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001; 33:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/85\">",
"      Mitchell SL, Budhiraja S, Thurman KA, et al. Evaluation of two real-time PCR chemistries for the detection of Chlamydophila pneumoniae in clinical specimens. Mol Cell Probes 2009; 23:309.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration (FDA) News Release. FDA expands use for FilmArray Respiratory Panel. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm304177.htm (Accessed on June 11, 2012).",
"    </li>",
"    <li>",
"     Idaho Technology Inc. The FilmArray Respiratory Panels. file://www.idahotech.com/FilmArray/RespiratoryTest.html (Accessed on June 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/88\">",
"      Schneeberger PM, Dorigo-Zetsma JW, van der Zee A, et al. Diagnosis of atypical pathogens in patients hospitalized with community-acquired respiratory infection. Scand J Infect Dis 2004; 36:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/89\">",
"      Dorigo-Zetsma JW, Verkooyen RP, van Helden HP, et al. Molecular detection of Mycoplasma pneumoniae in adults with community-acquired pneumonia requiring hospitalization. J Clin Microbiol 2001; 39:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/90\">",
"      Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005; 330:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/91\">",
"      Mundy LM, Oldach D, Auwaerter PG, et al. Implications for macrolide treatment in community-acquired pneumonia. Hopkins CAP Team. Chest 1998; 113:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/92\">",
"      Bartlett JG, Rosenblatt JE, Finegold SM. Percutaneous transtracheal aspiration in the diagnosis of anaerobic pulmonary infection. Ann Intern Med 1973; 79:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/93\">",
"      Bartlett JG. Anaerobic bacterial infections of the lung and pleural space. Clin Infect Dis 1993; 16 Suppl 4:S248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/94\">",
"      Wimberley NW, Bass JB Jr, Boyd BW, et al. Use of a bronchoscopic protected catheter brush for the diagnosis of pulmonary infections. Chest 1982; 81:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/26/26026/abstract/95\">",
"      Karwa M, Currie B, Kvetan V. Bioterrorism: Preparing for the impossible or the improbable. Crit Care Med 2005; 33:S75.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7032 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_26_26026=[""].join("\n");
var outline_f25_26_26026=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RADIOLOGIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSTIC TESTING FOR MICROBIAL ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Critical microbes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Outpatients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hospitalized patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Blood cultures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Sputum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Urinary antigen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Viral infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROCALCITONIN AND CRP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ORGANISMS OF SPECIAL INTEREST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Streptococcus pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Influenza",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Legionella spp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Chlamydophila (Chlamydia) pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mycoplasma pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Anaerobic bacteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Bioterrorism agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7032\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7032|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/26/34223\" title=\"diagnostic image 1\">",
"      Pneumococcal pneumonia CXR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/51/1840\" title=\"diagnostic image 2\">",
"      Pneumonia bulging fissure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/31/9712\" title=\"diagnostic image 3\">",
"      Mycoplasma chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/15/38134\" title=\"diagnostic image 4\">",
"      Mycoplasma pneumonia lung imaging A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/0/24580\" title=\"diagnostic image 5\">",
"      PCP in AIDS PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/28/28096\" title=\"diagnostic image 6\">",
"      Pneumococcal pneumonia complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7032|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/29/39390\" title=\"figure 1\">",
"      Microbiology CAP comprehensive testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7032|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/63/5117\" title=\"table 1\">",
"      CAP diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/40/17035\" title=\"table 2\">",
"      Dx Legionella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/10/4268\" title=\"table 3\">",
"      Bioterrorism agents CAP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29289?source=related_link\">",
"      Acute bronchitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=related_link\">",
"      Antibiotic studies for the treatment of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39880?source=related_link\">",
"      Antiviral drug resistance among seasonal influenza viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38199?source=related_link\">",
"      Clinical manifestations and diagnosis of Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22599?source=related_link\">",
"      Clinical manifestations and diagnosis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=related_link\">",
"      Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37513?source=related_link\">",
"      Diagnosis and treatment of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5528?source=related_link\">",
"      Diagnosis of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32680?source=related_link\">",
"      Epidemiology and pathogenesis of Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=related_link\">",
"      Human metapneumovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22247?source=related_link\">",
"      Identifying and managing casualties of biological terrorism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/601?source=related_link\">",
"      Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/5/3162?source=related_link\">",
"      Mycoplasma pneumoniae infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/617?source=related_link\">",
"      Parainfluenza viruses in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=related_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=related_link\">",
"      Patient information: Pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13386?source=related_link\">",
"      Pneumococcal pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7270?source=related_link\">",
"      Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1801?source=related_link\">",
"      Prognosis of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=related_link\">",
"      Respiratory syncytial virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17591?source=related_link\">",
"      Sputum cultures for the evaluation of bacterial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33015?source=related_link\">",
"      Treatment and prevention of Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=related_link\">",
"      Treatment and prevention of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40758?source=related_link\">",
"      Virulence determinants of community acquired methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_26_26027="EMPIRIC arm VT VF settings";
var content_f25_26_26027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    EMPIRIC arm programming of VT/VF settings",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Detection",
"      </td>",
"      <td class=\"subtitle1\">",
"       Threshold",
"      </td>",
"      <td class=\"subtitle1\">",
"       Detect Beats",
"      </td>",
"      <td class=\"subtitle1\">",
"       Therapies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       VF on",
"      </td>",
"      <td>",
"       250 beats/min",
"      </td>",
"      <td>",
"       18 of 24",
"      </td>",
"      <td>",
"       30 J x 6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       FVT via VF",
"      </td>",
"      <td>",
"       200 beats/min",
"      </td>",
"      <td>",
"       (18 of 24)",
"      </td>",
"      <td>",
"       Burst (1 sequence), 30 J x 5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       VT on",
"      </td>",
"      <td>",
"       150 beats/min",
"      </td>",
"      <td>",
"       16",
"      </td>",
"      <td>",
"       Burst (2), ramp (1), 20 J, 30 J x 3",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Supraventricular tachycardia criteria on: atrial fibrillation/atrial flutter, sinus tach (1:1 VT-ST boundary = 66 percent), SVT limit = 200 beats/min. Burst ATP: 8 intervals, R-S1 = 88 percent, 20 ms decrement. Ramp ATP: 8 intervals, R-S1 = 81 percent, 10 ms decrement.",
"    <div class=\"footnotes\">",
"     ATP: antitachycardia pacing; FVT: fast ventricular tachycardia; VF: ventricular fibrillation; VT: ventricular tachycardia.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wilkoff BL, Ousdigian KT, Sterns LD, et al. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol 2006; 48:330. Copyright &copy;2006 American College of Cardiology Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_26_26027=[""].join("\n");
var outline_f25_26_26027=null;
var title_f25_26_26028="Misc dermatologic disorders OLT";
var content_f25_26_26028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Miscellaneous dermatologic complications after liver transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cutaneous calcinosis",
"       </td>",
"       <td>",
"        Complication linked to the deposition of calcium.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema elevatum diutinum",
"       </td>",
"       <td>",
"        Rare condition due to a vasculitis whose intensity can improve with reduction of the cyclosporine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Photosensitivity",
"       </td>",
"       <td>",
"        Isolated reports: pseudoporphyria after liver transplantation for congenital biliary atresia, transitory porphyrinemia with light sensibility in a patient's waiting for a second transplantation after necrosis of the hepatic graft.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Porokeratosis",
"       </td>",
"       <td>",
"        Erythematous plaques round or oval, squamous with sharp border, porokeratosis lesions appear usually 4 to 5 years after liver transplantation and their number varies from one to dozens. These lesions are due to the clonal proliferation of keratinocytes. Porokeratosis in a recipient of a liver transplantation is a sign of a strong immunosuppression. In the context of a transplantation porokeratosis is not a precancerous lesion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombocytopenic purpura",
"       </td>",
"       <td>",
"        Thrombocytopenic purpura after liver transplantation can be due to the underlying liver disease (primary biliary cirrhosis), to an infection (varicella, herpes virus 6, parvovirus B19), to the immunosuppression (FK506), or to the graft itself. Endogenous heparin-like molecules have been described after liver transplantation and may have a role.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Graft-versus-host-disease",
"       </td>",
"       <td>",
"        Generally rare after transplantation of solid organs, but has been described after liver transplantation. The dermatologic and digestive manifestations are comparable to those observed in graft-versus-host-disease after bone marrow transplantation. The hepatic manifestations are usually mild probably because the lymphocytes of the donor are immunotolerant to the graft. In the case of acute graft-versus-host-disease the gravity of the dermatologic manifestations range from a maculopapulous rash localized to the extremities to generalized erythroderma and toxic epidermal necrolysis. In the case of chronic graft-versus-host-disease the lesions are polymorphic with appearance of lichen planus, scleroderma, polymorphic with appearance of lichen planus, scleroderma, ichtyosis, vitiligo and Shulman's fasciitis. Risk factors may include close matching of the donor and recipient HLA types, donor age older than 60 or younger than 40. Fluorescent in situ hybridization can help to reach an early diagnosis in sex mismatched patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granuloma annulare",
"       </td>",
"       <td>",
"        Confluent rash with maculae on sun-exposed areas. Histology demonstrates elastophagocytosis.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_26_26028=[""].join("\n");
var outline_f25_26_26028=null;
var title_f25_26_26029="Chemotherapy preparative regimens";
var content_f25_26_26029=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F50359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F50359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Non-radiation-containing preparative regimens for hematopoietic stem cell transplantation in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Combination",
"       </td>",
"       <td class=\"subtitle1\">",
"        Agents",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total dosages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Bu/Cy",
"       </td>",
"       <td>",
"        Busulfan",
"       </td>",
"       <td>",
"        16 mg/kg",
"       </td>",
"       <td rowspan=\"2\">",
"        Tutschka PJ, et al., 1987",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        120 mg/kg",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Bu/VP16",
"       </td>",
"       <td>",
"        Busulfan",
"       </td>",
"       <td>",
"        16 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        Chao NJ, et al., 1993",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etoposide",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        Linker CA, et al., 1993",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        CBV",
"       </td>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        6 to 7.2 g/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        Wheeler C, et al., 1990",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carmustine",
"       </td>",
"       <td>",
"        300 to 500 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        Reece DE, et al., 1991",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etoposide",
"       </td>",
"       <td>",
"        600 to 2400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        CBV + P",
"       </td>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        7.2 g/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td rowspan=\"4\">",
"        Reece DE, et al., 1994",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carmustine",
"       </td>",
"       <td>",
"        600 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etoposide",
"       </td>",
"       <td>",
"        1200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cisplatin",
"       </td>",
"       <td>",
"        150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        BEAM",
"       </td>",
"       <td>",
"        Carmustine",
"       </td>",
"       <td>",
"        300 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td rowspan=\"4\">",
"        Gassbard MH, et al., 1988",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etoposide",
"       </td>",
"       <td>",
"        400 to 800 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytarabine",
"       </td>",
"       <td>",
"        800 to 1600 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melphalan",
"       </td>",
"       <td>",
"        140 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        CCV",
"       </td>",
"       <td>",
"        Lomustine (CCNU)",
"       </td>",
"       <td>",
"        15 mg/kg",
"       </td>",
"       <td rowspan=\"3\">",
"        Chao NJ, et al., 1995",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        100 mg/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etoposide",
"       </td>",
"       <td>",
"        60 mg/kg",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Bu/Mel/TT",
"       </td>",
"       <td>",
"        Busulfan",
"       </td>",
"       <td>",
"        12 mg/kg",
"       </td>",
"       <td rowspan=\"3\">",
"        Schiffman K, et al., 1997",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melphalan",
"       </td>",
"       <td>",
"        100 mg/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thiotepa",
"       </td>",
"       <td>",
"        450 to 500 mg/kg",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Cy/ATG",
"       </td>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        50 mg/kg x 4 d",
"       </td>",
"       <td rowspan=\"2\">",
"        Storb R, et al., 1997",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antithymocyte globulin",
"       </td>",
"       <td>",
"        30 mg/kg x 3 d",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Cy/TT",
"       </td>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        1.5 g/m",
"        <sup>",
"         2",
"        </sup>",
"        /d x 4 d",
"       </td>",
"       <td rowspan=\"2\">",
"        Antman K, et al., 1997",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thiotepa",
"       </td>",
"       <td>",
"        200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /d x 4 d",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        CPA/cDDP/BCNU",
"       </td>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        1875 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /d x 3 d",
"       </td>",
"       <td rowspan=\"3\">",
"        Peters WP, 1988",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cisplatin",
"       </td>",
"       <td>",
"        55 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /d x 3 d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carmustine",
"       </td>",
"       <td>",
"        600 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_26_26029=[""].join("\n");
var outline_f25_26_26029=null;
var title_f25_26_26030="Sopher ovum forceps";
var content_f25_26_26030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sopher ovum forceps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These forceps are used for dilation and evacuation procedures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_26_26030=[""].join("\n");
var outline_f25_26_26030=null;
var title_f25_26_26031="Adenoid hypertrophy";
var content_f25_26_26031=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F58633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F58633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adenoid hypertrophy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 348px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFcAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Zt/9YK1bTqayrc/PV+BiCcUAe+fDu4/4lUY9hXf+H7oG/wDmPyg815N8ObsGyUbug6Vt3GszWN0drsI2PUUAe42Gpx2t8CzfuWOK2Nas0uUjuIBwRXlGkavDfW8cUshV/wCE56mvQ9A1N4rPyrgl1HTNAD7eFgSrCrcChWxT/wB1djfby4I61WuIZo8SfNj2oAlubNZDui+9UT27SJtYYcdqhM06ENGWFWINVAkxNGM9z60AZk0RjyD2qr/HXUmOx1FflOxz6VlXmkTWxLph07UAU0PQVKBxmqyEq3z5B9KmEmenSgBWqPbmlY5pydKAGocNirEZqAL+8/CrMa0ATIelTZ4qFRUmDigCwh4qcNkDFU4ic81MDzQBZQnnNOzVcMfU09XoAfSqM0gp4oAVRT1pF6Uq0APoo7UwEk0ASKeacSaaBTulAACc1IDzTB1pelAElFIp4pc0AFPj+9TKkj60ASdxTqacUmaAHGkpu4CgsMUAOopm6jdQA5jgUVGxyKKAPzLi4bNXIHAbmqSnFWIzyKAPRfh9ebGaPd16V1WuQPNbNtPKjNeX+F7wWeoqxPyk17FZPHdwKT9xxigDJ0HUGkhVCxEqHg5r1rwnqrTW4STJKjGTXlp0Q2t7vibjOcV3GhK1tbBm4zQB2KTyW8rSQscE8gGun0PWjcDyrlQVPTNcXptxufB5U81qgYYGI4NAHZssLggrtHY1n3NmjofKxu96h0+5aSPZcHBHSppnaPJ6H1oAoJ51o4+XHvWnBfGVOG5HY1FFcpINkoyD/FTJ7VVIe3OaAH3MMF4C3CTnqDWRcQvbEhxx61p/LJnzP3cg6H1pN+F2XQ3DsaAMqNwwz0x61PGR+HrS39gAPOhfK/3RVWF3bGRgelAF0kAZqaNgegqBEGPep0GKALCcinEhRzTE4WmudxwKAJVHcVKrZ4qBAcU8HFAFkCnDHpVYSVPHyKAJlp4qKM5NT4wKAAHinhcUypFOaAFpqoc1IV6U5RQAAYoalpGoAQUuaSigBwNKDzSL0pR1oAfmlXg5ptLmgCQtmm7qbmigAJ5ozSGg9KAFz70uaZg0ZxQA+img80UAfmaOtTLUIOKkDcUAaFgQzf7pr1fwZqImtxHn7leTWXyRE9zXS+GL9ra8TDYQ9aAPZw+6NJSoIzg1vWVxb+UISwLN0rl9NuFltfvZUjiokuRHIWVjuHQ0Adrbu1u+QeM1fW+dSpBrltM1ISuEkPOK1DNk/KenSgDsrK/3KpfFbUN3Dcr5UjD2rhYZWMI+bmpIbpwwJYjBoA7J1MTEMBt7U+GdQcZ4rOstRS5iAmbGOM1b2Lwy/MD6UAXZRHcKACNwqIAx/LKNy+ppixMTlOKcZmX5ZOaAJ0gK/MmGj7ioriwXmWMH5ucU2NnjOYidp6itC2uTgDj6UAZqKEGCpzT0UMcYrcVYJhgqM9c08WMQ5GKAMnanl7e9ReXjrWpJBHuJxtx61n3LgPhe1AEbPsFJuBqORweDxUKMdx54oAuIBmpAxHSq6bm6HFWI145oAswe9TFs1XQ4qRB1oAmU+tSriq44qVTmgCfrR+NR0hOKAHlqQGmE0goAkzTlHvURPFCsaAJyueRTdxFCtxT+CKAGq/rUnWmgAUuaAFopM0ZoAdRSZozQAjGkp2M0xlxmgBwIFFQM2KKAPzUqReeKRRxU8Kc0ATxgqgrS01S0ynOAKqxoMZParFrLiSgD0vQ77NuEUngc1ZaYcnPU1y+gT7Dk1rGXdOD2NAHT2JxtcHtW1BfB02L9+ubtpdsIFSI/zBgSMUAdlbXEoHNWI7sPNseqNiwktFPerSRhmD45FAF6aUx4VGIU1u6PqbjYjZIrlXDCTcOlW7e5EcqbuKAPQ0ul3Zz17VO0scq4Zce9cxDdowUg8n3rRguD0FAG3CIz92rf2DzQDD97vXOF3hbdk/nW9ot6xhJoAe0UlsvznnpT7W7JfBq410JcB1BGM1EbaKZsoQrUAS3RQxjdxmsa8t2CB4+ma0LtHiUCQZAqt56ovOSp4oAyshjtbrT1QZq5JaRyHdEcNUAheNv3lADkXFTx9KiU1IHxQBMKkU4qkH5609XzQBbzSq/NV1b3o3D1oAtFyKYZOars/vSbx60AW91KrcVVD+9PVqALOactQg5FKpoAsA0/dxUS/dpp60AS76N9RbqUHPSgCUNzT91QYNHNAE+6jdUQ6UucUATKaVhkVEr0pagBjiinE5ooA/NiNCauxKEHUGoQAhx605j0xQBJJIeg4qWxyWI/WqpOTVyyU+aMdM80AdPp4Pkgr1PataMMCm4EVX8PqjSBW7Vv3FuHHyjGKAJ43Xy0UHnHWpbYs0hQggetUoIio57VqwupWMgUAdHoshCbD0rcVkSLbjJPesLTBlcitAsSdvpQBZmyUABwP71QopaZRnNXrVd9swxlqpj/AFxB+WgDbt4SOQeKuw3flMMjoelU9M3CIEnIx1qeSMSDjrQBqT3odVOK0dIvgtvJlcD61zE+Uxk1a0yUtBKCeM0AdhZ3SuQQwrQUeZIGX5fb1rh7WWSKQMDhBWza6z84HpQB1V0BIiq/pWdLYOoJjbcD2xVlr+OSBH9qq/25FHxjnpQBXhjeFz5qtitGFA4/erwehqJNbjPLxKwqzDqFvcqUAwx6UAVZ7NSx8uQAVSlgdTgc1qvaSKcg/LTWB6YoAyDDIvJFCtt+9xV6UOo+bFVS8bH5u1ADlORwKacjrUqFf4abN04oAiLUVByCc1IrUASCpEbHFRinoQKALCHkVYCEDrVdGAxVuNgRQAgOF6UhGVyKl2grSxw9D2oAgRC3bFWI4sDk1KFAooAMDGMUmwUppuaAF2CmsuRwKdmlWUA4oAiI29RTCeakkIPSoyhxmgBVPNFRDIbmigD85m5NJtpU6GngUAKorR0pFLOW61ng4rQ0r5nPHWgDsdDjQTRkdcV0tzwikVzeir8wb0FdOybrdT3oAEXfhj6VICVYEUsCHjHSrKxh88jNAGhpE3zDNdDIFaAMvLVzGnKfN24rqbMARDfigC/o0DSQN64rMNpI10yMe9aNtcGGQFGyPSsy7uZG1AOpwPSgC/byTRy+T2HFbKQMqqzgkGsqGeJWVpCNw71pHUBIF8sA4oAdqar5aKEPFRaPP5WoIhGEbin3MpuXBhYH1B7VWkUwfO/BByD60AbGuf6PL5a8xt82RWdbSMH4rXgkh1TTxk/vl6e9Zc0RjfAGDQB0mm3ge0KMeahuz5ZyBnNULdJIoQy896mkm+0xbUbbIvJHtQBOlwoi5O2lt9Q8kE7s4rKLZBRxlqRV28Y4+tAHXadr3mZTbir32wufrXH2EhimXIypro4ZVZwcYGKAG3pPmdaiHc1fmsmmG9D+FVHglUEbOTQAsDZqePLLUUNu8abm6ntV+3jKjkUAUjblic0w22DWqVB6cVG6nPAzQBmlCtRmQg4xxV9gCfWmSWruvyJ+NAEKScVagfnFVFtZU7E+1SAvCBuUg0AasJyRU5OBk9BVSzYNGD3z0q95LSIRigCs9wvQUiMT0BqdLAKdzmrCRp2HFAFLJ3jI4obLH5auuqL2zUeFY4HyigCmxKcHNAYYzVme2Zl+Qg+9UmhkiBLDigCeMgmrCpk8VnpxyD+FXbZyAN1ACtbgnJoq6CpXJ6UUAfmavSnikFSJQA6MZrR0tcTVRjHzCtXTV/eEj0oA7LQo92eOa6q3gBiAJA+tY/hiMGHzX6AYp+oXbedsTOO1AG1DboJNzMNvsatQwQM+Y2GRXLRzy5CsxDHtWzZW9wqCRASO9AHQafbqJCeK1BGpjIyciufgW7xlUINXrUXbMTIdgNAFzT5I0uMMxJ9DTrrYxZxwR61XtgsVyCV3Of4vSnXyuWbI+UigDNubwlioJ49DUlhrJimCHJ4xVAwk5CnHNU3eOC4G45OcUAdT9tCSB1kKqeozUl7rCyRBc7lHSuQvZpPN+Q/KRUcEzhSDxmgDtdK1R45A8RIUdq7LTZo9QTecbmrzHRbswSgyJuQjGK7bQWIuhLB9xuq0AdcsJt7RmcgqBxXOTM5Zp4Mgg8j2rf1Nt1uoDYyOnpWZZQbmKA5BFAEULC8h3oMOKs29s8uFIIPuKjntpNPmD7SUPpWvbXMRiBf7xoAiisSoKnk9q0YIGEQU5BqzYxrNtZTWwtsoI8zkUAUbSSXy+OlTmVsDCgkdauGzJXMXSqjjYSrCgCOJRJLmU8egqxNx90Z+lFvGlWdmzpQBQ2OwyM8dqdDG5+8DV3zVVwvc1KY3bBHSgCvHYCT5lFTR2jhsDGKv2pOMGrBRcZbrQBmvZ7cE4oks4JAN+3NTzxM3K0R2pcAnqKAFisIYgOM/SrXlKVwBiopWaJNq9aZDcsM7+aAJ/IUD1qJlQDkDNSrKH5zxSuFZTigDKuJVVuMZqhcTTM3yLitC6txvyelV5lyPk7UAV4mkCgyMQx6ipUIY5dsj0qNcFiHPzU2QYbA6UATlIxyMUCVF+8OKzkmIJHamzXIQADv1oA1TcgjCdKKx0uTvwOhooA/PWnp1qOpEoAsRDLVs6WMOMDNZNuuW5rodJiyd2O9AHcaMmzTCMkZOaddwY8t0XJNO00FrIAA59KvqQIdz8Y9aANfw7pVs6faLqMHA4q1cXsEchVECKDjiuaTWpYbhUXPk1LeX0d3JthwGoA30vQXARjzVqeZYofMlJx6Vy0M8sLqDjNaN7eiazVZBzQBU1DxAsUmINv51Fd6zPNFHIhGG6jPSsS9sxI5ZeDUcjG3s406mgDUa9LR/fIbvis+aYlx/Fz1qlY3AZ3DVZikR2IHNAD7m9fz044q/kSIhBwaoMqPKuavJGdwC0AbGmBkddwGDxW/C00F1E8UjIo7CsbSIJHlXcDtrppYB5a4HIFAHW2dwmoWGcfvBx9asQRSWOJFjEg7881jaBO0cOzacetbkU8gYOg3Y6g+lAG/aTWmoWwMi4x97I6VKNLt5GHlqCvao9OiSSLfs2F+1aEdsyDMT5I7UAVvs/wBlYbFIFXYLhWx5hq1btvXbOufSkl01X+ZDigCzC+0Y7Vj63rmiadqum6ZqF/Db6jqTlLWBuWlIGTjHQe5wM4HUgVifEPxraeB9MhaWN77VrxvJ0/ToeZbqXoAB2XJGT29yQDS+GHgS402/n8VeMp01Dxlfr+8l6x2UZ6QwjsAOCR1/MkA7aK1KngVKIWIwa0UwOgqYKvagDFWyCNvLMTngYq9bqZBg8VaeMMKI0CdKAEWIKaJVzjFObJPAqC4Z1xtzjFAE0aEDJNPPA4qrbysSAatUAVboF4nxww6Vm2jvscyqMitiT7w96xNRl2TMiDOfSgCWMs8gKk49KvOWVcgfhWfp0q9Cwz6VqBg+elAFN8yI27is+WURgntV+6fYSBXO6hdiObyjyDzmgAuHYTM2eD0qaGYumG4JrEnvGlnJIKp71q2bCVAR1FADmUhSSMGs+RXySR1rfmiDRZHX0qhOqqgyMH3oAq26soBxmilMnygKe9FAH58mpY+lQA5HNTRHNAF+AcLXRaSSsiisG3GVFbunNhlOOaAPQNH+aI+uKt3sJCqp5U9aydJn2qMdTXTxW/2i2HdjQBz72u5RtHy5xSyaRPayR3CA+WeTXTLpgCIgzu6nFayQB9NZHXJUcUAcYoLSq7LU9+jeSGTpVwL8jLKgXB4xVi8tD9lEicrjpQBxdxcMjgEc0+4aN4145PWrs1p50uSACKrNYuWxnigCpHYK2WXADVJBp4SbMT8+lX7azmV8J82exrqdL0hUjEs0YyaAOYsdJlZt7KWNa8FqysP3XPeuneFVULCmDUttpbz43ZDHpigCjYxsu0kYAFalxKkcKHuabqOk3dlHuYHyiOvepbPR57+yE0YbCevegDT0WZEhIfqRwaWTVzFL5UQ3OTz9KpRSfZInhmXbIRxWfaArK0khO7PBoA7u21ny7UGRsMO1XdO1yWX7qcZrjLB/OuMScqe1dLbvFCmEOMUAdnYagsyBWUBh1rC+JHj6w8FaTFIY2vdXu28mw06DmW6kPAAA6LkjJ/mSAfAviZ8abzw14yh07R0iuLa0Qi9RuN7sBhQ3baOfxIPSrfw3D6nL/wAJpql/Hqeu3i4jkXlLOP8A55Rg/dIyQe/X1JIB6l8O/CE1jqcvi/x1cR3/AIyvEwFXmLToj0hiHQYBwWHvyckt6E+pRY4xXnVhf3IYNK24+9bSXquoJxn0FAHQyao4PyGtG11IPXGPdgYxVqy1mGKQiZdoFAHbx3AbJ7Cs64vnE5VeAKq2t8JyHhw0ftUmqRM9oXgX95jpQBo292Hj5bLVMW81M59q4DTtRuoLtluEwB1rqtNuJbl8gDyj6UAasexPrTgxBzVWZtjEUwSlgATQBPPIqfPI2FHeuS1rxDa2EEjq28k9a6O7ha4hKZGzFcT4l8MSXECx2+Mk5zQBj+EfE8t7r8kZU+WT6V6Q1/EhUKwBY4ri/DugppjGSXb54GOKfeiYXCupbg5wOlAHXzTIwbLDIFYuoNAQh4JFZ89zLFEZjnOOQelU/NMieYGyV7GgBk8gmlfn5R0FWtNvfJQgdR0rHt2ae5dhwM9B0q3uCtnHsaAOqt7vzQMHimapgxhhWZpk+3cO2KuzEtb7iRjHFAFON1VOeTmiqqyr5hHWigD4HC5+tXbaEnGQaZDDlutbun2YkCknigCWztMheK6bSdL3MNykfUVLo2krIoZSTit63iaNgAG4oAv6PpCFhkgYrudG0BjGScjuK5rRg7sFCnkivW9IgxBEGHO2gDA0/RWCPJIpJBwOKU6eFmKbSFIr0W3sIjCo9RTZtIhJyaAPGtU0siUrsIGeuKgjhkWExuhCDpmvXdQ0mMwHKAjHBrjL3RXYl0J2dhQB5zPp8juxjBHPAottFnkcZBFd1HprE7Nh3HvV22sjG4V0OexxQBylnohhMe7kjrxW8LE4UY+XvW6LRlYgx596vWNqxYLLHhT7UAZNlZRSFVCZP0rf07RPn3EYweARWtZaZEo3AYNaabFAVT8w60AU73TIrm0EcijGMdKr2mnxW9ssUYCqnX3rZ3HaeMmsLVNWW2UjaCRQByPje3h+0I0YAbPQVyN7MEkG09sVq+IdTN3cmQDGDiuflGZdxPuKANvTHwuScGqfjTxG3h7w7cXcSNNeSfubWBQWaWVvugAdfU+wNVrS5Imx2raiVXkjkZVMig7WI5XPXB7ZoA8M8J/CS/1W6bUfGE7wea5laBWBlkJOSWPRc/ifpXsmh6RZ6PbrZ6ZZpbWq8hUHU+pPUn3PNbHk9yc1LCoXuaALgUAgdsU5WMbccg00nimct900AX0kDY45qvqhCsqP/F1PpTlnSKMD+Kql/cry8lAD7fVLq1uY4rTJiB+b3r03TbkTWkTMQWwCRXk1leRvMMDBFd3o0x8kduKAN+W1t5Wcyxj5u+Kmh8q2RViXao/WqIv40TEpH41Cs4nk+RwVoA1ZhvUsT9KgQY60iS4Gxj9KegzQBOu0QsWP41Rnuo1QDOSKlucRp87YU9qymslXdL5uQegoAiu1WTLJnJrNME5lweg9a1rSZS5RhyKnFqXkLNnFAGNcwSS27RsvBFYclnJa7xnr2rs7i1YK20npXL3jSOJA4O/OKAMa0uhaysCOtakEqupYjIrDZGjuSrrkA81peepi2RjHFAFuynDPtA25NalyxSDbngCuesHJmJPatOe4VoGGecUAVFlCuTRVESlM59aKAPi6P5nHb6VvaQxyFPSsOEfOM1s6fxKnoWFAHtXgHTg1l5rpkHiugudFBnykfB7Cpvh1Gsnh1GAzg8mu306zEtyH27sdqAMbQvDRjMUjKeuRXZJtgIBX5hxWlZ26xrkjIPQelY2tCQMwi4Y9KANmK8hSLcxwBwBnvUNxqapCXkOxfeue0rTb0SiW8dmjJ4X0q1f2EzuwmbMR+6KAG3F690d/nYh9B3pLNPORs5KjpUUGnzKyxuB5HrXSWtokcRxg4HagDDtHX7R5ZjG7PBxWhcxwmVMqMj0p4giFyGwBz1okRXuDg5GKALEVtDOiNg59qvraxEAHgiq+nptjXHIq9t3nPNAESqEbaXAqsYWiuGkDjaTk5qe6iTYXGciqWftUDpkq2OKAH3N0SD5RGMYzXFaos808m45UVda4mtpXiL7lFV1nMjPkcHvQBx19BIrlNvBOazbmMo2CCCK7mVI5XBZRxWdqFjDO3y4yKAOUjUqu/vWlY36uQHPI4qe700pD+7BNZa2pU5AIIoA6aBt3Q8GrCqFbrn6VzUdxJEMDNSQ6pJFJl+VoA6Qvjg09WVUZ+mKp2lx9owce9F/LtQIOM0ACSF5i5Py1S1SYsNi1JEx8rB61VuUw249aAEsDslU8ZHWu4tb9IbQMWHSuGVdxBU49a0baKWfERyKANHW/EAki2J0HpTPD+vmOZYick881l32kS5LDJUd6pafZzx3YcAkDvQB6za3yXToO4PY1tQMd56Yrz7SfPSdG3HGea7SCYmBmB5oAs38kbxlSRmub+2FZ3RM7R61T1i9uBNhATg1Ua5lk5MZQ46nvQB0Nncwk5chTWgLvemEdTj0rl4rdpUDbsn2q7awNA24MSPSgDet54pMqx+aqV5YB5S+OT0xTIIQzbt+01o7gAuG3EUAc/wD2OwmfemQe9Z13pj25ZoVJ9q7kyq6DeApNRfZI35DAmgDz6GMx53AqT61XllYvgDIHf1r0O40aC4iIIGT6Vgz+GZkkwh/d9vagDlZGJkBGMYorqh4eEZBOTRQB8HxLlq2LFMMn1FZsC/NWzar80e3rkUAe/fCeffpEkB+temRTLbWqBRiRjwa8c+Gt6LG58mZsLIor0+4vInaBEcNg0AdjZlhbpk5Y1dSBJRmRVJFZcUyKiYfAAqOTUvs6s+/IoA2pFjx90DFUr0xsvTpXMzeNY4JSsiFl9BT49bF+uY4yiN60ASX+pLBEVx0PFVxrcptQkYJY9afqlgslqu5vnPIpui2ShCzqDjoaALltNIREX4J9a2bS2ZmLkjGKxb9S6AD5cc5qvFrLJaSnzPlUYoA6+z27VAI461bnIVcJxXnWgeMYIt0VyfunAarV94xgkbyoW4bqaAOwlk8yFgrDPeufvdRSzXbuG/pxXPXGvfZLdnjlOTz1rjbjVri4u3mEh5NAHRatfodRVon5YcimPebGXB4NYVlE9xIZmPzetXXOBg8kUAaiXYOeKiEwaXFVI2KjrxU9uollHtzQBpSRqYQDWJeQ7ZfkX5a2JWDAKvaoTtYEY5oA5q5ypOF4qm6Fk5OK6K5tww4FYtzD8xXOBQBLo920a/O1W57oSOMNmudvH8kcZWotPvy8hUtQB1UT5FWFjEjgNVK2yVB65rQiBDZoA0ILSJVGQK2NMto1JkZRjHFYqTHZhRk1qT3nk6cgU4oA2LBbeRZEkQEVTm09I2JhQc80llOq26sT97rV2AtIwOcqOlADtLtXTl0ABrQlmWOJh0p8cy7QrVl6wxAO2gDGvpYzOwJOait5ypPmDKVXZN0pJBNMdZSfmPy0Aa8eoRxHIPy1a/t63VAcZri7yYKxVW5qvHOwOCcigDsLnXQyMYztqqfEksI+Q5Nc2XeQ8Hiqk6MqliTQB1Q8Z3KSZkUFa1LXxvC6gEYavLmnLMRyaFfDbu4oA9oi8UwEA5xmr9vr1vIfmdcGvDpL+QL97pVW41u5iXIkNAH0C2oW7H93ImT70V83t4pvEP8ArHx9aKAPC4hitWyIWWMN1JBFZ0B2hgR1Fdp4X8OyTiO8mB2AZGaAOy0nTpZoYbogoNvyn1rrNGjl8wAuWYcnJ6VS0GZnCxtH+6TpitGF3e4cQIQOnSgDok1JohiV+nao7rUzcYhjPJ7Vjx2dwWdXznHFaem6W7IXJO4UARw6cry75CDW3YPGpA4CL1rNNjcLzk4JrX07TZFQFs80AXZ5hJF5gX7vQVHYPNcxlYQVGelbo09BbIMdetXrKyitlAUAZoAxZbGR7by2JyetYF5pPkRPHz5bd8V6GY0h5kZQT0zWJ4jYCAYZAPWgDx/WtOOnPvYExk8GsczfOSG2gdq7Hx/IsOisRIrPu4ry4SzykHnpQBvzXpfAMmQO1OhkXGAfmY9Kx40Yryea2tFsJJ5AxzgUAdHZsqWyqD83elVvnz1p628cIG9vbFTRxwdeaAK+WORjk9BV6zBjjORh8URWe47x06ip0jLNtPFAC2+MFmNQkhWYn1q28Squ0Hmq08RC0ARMd3ArPvbbuKug7etKwBHz0AcT4nbG0YxWHbSYkAzhhWz4mUiUg9qwLRCbgN2zQB2GmXsioqsK6m3YSJleRXH2WABmuq0o4g5oAkkcxZbdgVt6NPb3FjtusZz3rAvmGzb3NQ20/lpt3YHegD0LNkVhijKnPQVYkxE4VVwMc1xWmF5D5kZbC9K66C5UQL5nLEUAWM55B5qOcK6HfVeS664GBUEN8oDB+R60APW1j2596iv7bNrJ5QycVLcajbxqAGHTNUW1RSSFxQByctq4nPnZWpYLUHiugaOK7bL4z7VNHpUAwQTmgDmrgLAp7YrIur1GBXeM11fiDTcQkocrjkCuOlsotzblbNAFSN1UckVFNdYPy4IqWW1XACb8+lZWpQXNshcRHaO9AD7q92jnFY1zdNIzYf5e1VJrhnJ3HBHaqsk+B70AWmmYcEjFFZU10aKAOOUhRuPSvdvD1sG8Hac0fzNKo4Hua+ebm8Hl4Qk/hXs1l40tdN+HNklswfUAgj2gfd96APU9PsrSwsAzsolxyuaraff27XEgG1cHNeW+HfFchgf7bMzTkdG6VFLr0guQ9vJk5yw9qAPdI3ikkWUONpGPxok1W3sm2bgc9a8z0jxmq2jxyAk9jiqupeId/EWWduuaAPXk1uxkRYxMhI+Y1a/4SewhUfOmB718/wAN04dnSZwxOGFaWlQz6lepa7pMP3xQB6/ffESzSJ2jdcJ29a5qT4tTA7/szMueOKjs/h3HM6GSR9meeetdXD8ObF0Q4AA7YoA4q++Imr6lKrxW8vlDsFrB1nxxq2oRiGMuhU8jbzXu1j4ZtLO38uGCI8YyRWDeeENKs9RFz5Kl359qAPELi7vtQ8tLtpAi/wB4YzU8MLjO0ZNeq+JdItLqwcpAqOvQqOtcppPhua9+7kFTjrQBk2GnGZhv4Heuqt0jsLcKpO4jg10ul+DVjgHnN831qGbwpdSagmD/AKOvHWgDL0+zN0N7ZY5710Om6Cs6sXGAK07Dw9JBwrZX3q+IzZhl65oA5y+0+SyTMZynpVOJGmAwMc1p3l47uY8ZGadaIGcDbigDMu9LuVXzUYkelZ7XDH5JVwema7S9nS1hAY8fSuQ1SeKYkrhTmgCnLxjnNRO+RyabK2Ixk5qu8gAyTxQBz/iOPzrs9xisLAg2kDFb90++Z2P3T0rDvUODn8KANGxuRLgA812Ni+2zHGGNea2Ehjk/GuyTUP3IAJ4oAuXs/wA30qtp+69uAqdmGayLu/Ys/pnitnwtJ5c3be3NAHX+ctlD5YxTEvZ2GVGRVedGll3MQR9akhtpXPy5C9OKANmylF3EyDh8Vhahdm2laDOPWtCy8yyuAG79aztdhWeVpYzlqAM+Sfcc7qj85s4VuazJJyrFScYqI3P+1getAHQafeOjlpZQFFXx4rs4/lkcN71wN9fbFIjkznrWNJcDaQMmgD1X+27S4bdFOo/2T3p6rFdDcsaZ9R3rxqSR/vJIysOmKu2niO/spEYTFlX+E96APVZ/stpC0lxCMjoDXJ6xepfIwhxGP7vrTB41tdZs/s+oAQSgdQOtc9qeo20RAil3AdxQBzN8THduDxz1rPmlIJGc1Nq10srkoeayHlOOTQA+WT0PNFUZJeeaKAOR8uRCT/DWto43RhELFs5APSm+XvxxwOtdt4EstPulZZgvmA5BoAzxDcRIZJLdunUV0+h6QlzbRs2QXr0C20aNrQoqpKjL0Iq7a6BCscBiKjaeVoA4i68KXFuMwNlcZqTQvD01yxeXopxXojxBGKvjA4qeG3igtAyYAZucd6AGaH4O0+OLzLiJXbGc119hYaXaXCGK2jXI+9jpXNtqXlp5aEkAVCl/NKdqlh6UAd2bqKOT5CNoqzHqqHJU5NecWc1ywlEkjk54zVvS5Zbac+bIWHoaAO5GqgZLnFV4nXULg5bIQ1iF1uJASdoNaOnyRWVzggbX6mgDcms7URbJUBHepdL0uzjBeGMD8KYWEysFOR2NTaZcrGTC7UAXTbxnPYCnLGij5cVC843ED7tRvIMZXoKALMj4Q5xisDxBMERAvVjVuS8V+AcVha3KWkUdh0PpQAyGGKWQKSNxrSMcFnES+M1k6dJCJdzP8/vVfWrp2Zsn5exoAztdv/MchW4Fc9JIX7067YyE4NVhtReTk0APkk2qMnNU7u4CRZpJZMsSx+UVj6jcb32p92gCMz5zVS4bd1p2Ao5qpcyjaQKAEUrvG31rZaUohFYVgcvlua0p5P3eM/NQAKzSyhAMgnmt7T/9GnR1ORxmsa2HlopyAT3rSgfgfMuaAOvjmjul/dHDCnrf3EBCowODXOwylCGRiufStIFZCh/i6k0AbttcmeYvN/CM4qrqBjk3NGcE9qc8kVvYF8fvG4FY8skjHJyBQBhazFNFIzDkYzXOSX0mShyO1dteqZ4Sori9WtXt5cleM8mgCrJKx6tUDPjimb1JPOaiZ8gmgBzSc8VWmk4pJG4PNVJnPrQA2eX5jlePUVWaRgCR9360sjZB5qpI3WgBs8pNVZJODmnSuM1Rnk64PNACyyUVULk9TRQA2M4z71qaLfNp90kigbO9YgcipkkyMdqAPbPD3iNHVXim6jBUmuktJ7yeLz4F3KjZbFfPmn3EkUoMUhUCvZ/g94hEoubK7fJJyPpigDq55JLmLMZG89u9QxzToqRzhsCtG9sJEkW5syHQcsB1xRaPDcMVlR1f/aFAFG33LcsZOVPSrsdz5cvygYqO8t/KOR0qNUOA2M+1AGlbSbwSCuc9qmmYM+Yzlh1FULaM+Z8qlAeuasyFYLjaBhuPmNAF5JR5BJyGFSLM0sQVzhh0NRpA8iZDde9NEFxE2XBK0Ab2k37x7Y5HGOlXb19pEkZ+b2rnrZwTlYzx3q0LwH5WbFAHQ2ly00P09aoXeqeQ7Rk8VjC/aOcbZPlzzWfqtyst1u3cZoA0rq/kG51J21S/tgXETI5w/bNUbjUFBCAZXFZF24aTcikA9aANOS7KSckj3FJLfCQEGTIx3qgpLx4bjjiqM8sMH3myfSgC5NcRnITO6qLvsVmkYVQm1NA2IkzVTc8z7nOBQBPcztIpA4XtWW8pHA61clYAHaeKypH/AHhoAsF9y9fzqjOOakaaMDLtis28v14VOaANS0KRruY04ybjnNZsDEx5Y1aR+KAL8d0F4ZQcetWotRjAwYvyrLh2M/zjJrWijjEZ+TPFAFqPU4NoGWzWjZanAzYEgB96wIrXzW2bDmprvw7dLAHiRyO5HagDpr7XolmiTAaEDkj1q0t5BcQbkOc1yFvYGWAR7jvHBqbT99pcGN2O2gDZmmaNvl6darXaw30RVxgmlkbeDVRw6gkdBQBy2qae1pMSoJT2rKdxz2ruFYXStGy5PrWNeaEZZNqgjNAHLyyLyN1VJZARwa6y60iy0+Emdtz4+7XM3scO9jCpAoAznlHTnNVZ329afcnbzVKaTNADJZRnvmqUrZJNOlf5qhdqAGs4xRUEjYooAiSZWXg5NSpJ71jQuVbjpV5X4oA0opcHrXU+CNUNhrCOHKq5CnB61xSuegNWba4aFlKn5g2aAPpqy1t7eVNrHYRnIPSuu0doNWtHnUqZOme9eEeH/EAubVFkY7gMHNd54D1R7a4ngLnB+ZfSgDuZrLcTHIOQKp29lIJTx8oNbsFxHdxxnI81h17VLgRxM2MjoSKAI7KCO5XZIgBHfFWZNKtvKYv847FqpQagkEpVMEmm3euRrGY349MUAadtpKJCCkhwe2asoIXxFheOtctJ4iaNFRMkeoqGDVXSQyFiBQB24t7dI9oVVA9BWDfWEDy+bvKoDyAayrrxE5BEZOKyLjXZiML0zQBbv2jt5pFQk56ZrLuJSxzn8KLi9NxIrlcDGDVdXC5eRgB70AToW25Ipk99DbxEuwJ9DWHqOt7WMcJyfWsV5JJSTI/B96ANm61ieYkQ/KO2KpF3c5kOWNV4Yz/Bx9amHlwktI/NAE0aleQBSlkQHzGx7Vk3mqhTtiJzWbNdyzffY0AblzfxRxtswcVzM2pmWZgp2/SiVyIyATk1iMzRTmgDXlLMuTIx/GqKvumCg9DVcXLnjNTWq5mDZHNAG6HxAoq1bBpCTj5TWduyQB0rYhkEcSoOo6mgC/Y29vEQZyxY8jBragmgBwiEj3rDhcZzV6165349KAOksnjaXDQovHDYrsDJHHoP72IYPQgda86jvGBO/oo7VYv/ABbdQRW0Cputx97NAGpKbSKcPFGACPmyKzNSgRozLCOc9RU6XsGoRk8Bj0AqSERLG0bn6UAUFDC0Vv4+lMuEcwbsYxU1+rRW++MjAPSq0N/HNGI5cjsaAKCyGF9ynn0q9BclwzsFyBSz6SktuZoH6diawZWe3fbJuHtQBj69LLNds7HIWsO4ciumvreOT5kkGD1zWBqCJGSMg/SgDDv2GwHpWVO5xwav6g4Ziq8YrKlOTQBG7c81E560rcGonPWgCJ260Ux6KAMocc1YikquKUdRQBfjfnNTI3Oe1VIzUoagDX0m5eGYAOeTxXpfhnWMSDJO8jBryJX2kMOo5rqtJuCRFIpO4UAfQmkakRaowY8cda7HT7sSRCJ+jivFfDeptJbFXOD9a9Eg1JVsIZFPIx3oA3dW0SSOQT2pJBHNctqCyQ73KFzXc6bqYu7ZRnt61ma3aIgLY5PpQBwVtdushlkyAv8AB6019YkMm3YdlWtWtElOYztcVjtHsfa3NAGmt4r4wSM1INrYyaowQhcMeFPrUd9qcVmhRcFqANO6u4raLJrnL3VHuiUBITtWXdXU185PIUe9Pt4cAbjwKAJFiBOQ2SatxwrGMyVTuLyC1jJ3DPSshtUkuiUGQPXNAGze6qkSlbYbyOCB2rCuLuaYkyOVz2qRZ0tYzkAsazXnDyFj3oAsKxHfNIZTmolmHrSeYvqKAJWkLCq00WRuxT96nvVPULoKMBqAKkhKvV6yc7hWNJcAuMmtGykBIwaANwP8wq9DeknJSsQP8/WrMb4wpJyaANs6mRgLGas22oy5BEZqrbWiiEMSSW5rRs4to4UnFADn1S6SNmNudta2lyJqtttMIDCuk8H6PDqSt9pXHGcEUt7BFZ3EkVlBhVPJAxzQByklvcaZMH2kITWtbsl1FlT81aEEsdyfKuhjPHNZGq2kullpbbLRk0AR6qZVhI/hrDMnynnmrGp3d1LAvlDgjJ+tYsr3pUBUGT7UAbE97Mmmn7PKQwrm59RvJV2zuCT+dS3Ul5a7cgEEcislryFpCXRh70ANmuZIpQr79rd+1UbyfOSCTVq8likhYo2SB0NYs7ZNAEM0m9ifWqco4JqzJgVVc5zQBXk61C/3TU0nWq8negCJqKa/WigDMFANJRQBYRqmVs1VjNSqaALI6Vu6RIfs5x1rBjOSBWtorEq69hQB1mm6m1uAGbnFdjo2qzT2ix7iQDnNebrkyYI4x1rW0u8ktpV2MdgPI9qAPZdG1cwHy3fHTBz1rq9RvGm00spG8Lkk14Bf6zPPMn2ZiApG3HrXsPh2ZrjR188/OU5oA5+S5nnLqeSfSooyI23swJHWrGozxWzPg4PrXI6jqzyyNFbj5T1agDW1bV1DskXzHoMdqySjyfvJjnNUVljt4xu+Zv7x71nX+uLESm/5j0FAG7NdxwDGQFrLvtbVVKxkn0wa5e5v5riTknZUYZQOWoA0Z7t5wSxOM9Kkt7opEdvWsoy46dKWGUiTB6GgDWeZpUDMePSq7TYbPb0quZjtbFVGnPrQBqiegzEMB61lLOacZyWoAvT3OxetY93d72PWo7u4Zn256VVVGc0AP84+YBzW9prcdeKwUgJcVt2amMAetAGshy9aVjbeYyvIwXnoax4X/eD6it9WUygDgUAdPavCIFVRkjqav2zlfuqM9q521lCEBT9a1o7kKo5oA7fRdaisGxIy+aFzx3rlLvxhdvfzt9n2xlqzxIDKrk7snrmrMcMTXZXAdG60Aa9lqdrqfU7Ju2T3q5NJI1pJA43EdKxJvD0c5LWsphk/hA9ak069ubGf7Fqy44+WQ96AM6eUoSDwBxWc12FcbTk1PrE8Yml2HK5rC86WRysEWSeM0AXdXVpFjmiJJbgisaXYo2yqoqa8W+iVg4xtFYlyZ+GmJ570AJfKiMTEeKz365qxISQMfdqvJ2oAgk5Jqq4wTVl+9V5O9AFeTrVeTqasSdarydTQBXfrRQ/WigDMooooAKkQ1HSjrQBaVuK1NJfFworHU8VcsZvJuEY8g0AdSZBGCe5NOFyFU46moUs5bxt0DBlI6e9XLHRLt5groevpQBqeE1ub2/T93iNSO1esX+uW+kWJiODLt7Vw1nLFo1kclVkxXK6x4gNzKSz5I9+tAG9qWuG9lJOQueTWJeaskIIXFcxcarKzsq8IaqSTs5yxzQBr3erSTMQudtVfN3LknJ96oB/ypfMoAueYPWjzB61T8ykM3tQBd80DvTTKKpmammTNAF/7V2pjycZqmHxSl8jFAFtZPeh5MCqobFNkk3DHSgBzNkmpIjVXdj3qeDmgDSt1wRV9T0rOiNW4zigDQiPIrXhvIlbhTWJF061pWXJBIGKANMalggRx8n1q5Fd3Ug5VQKZaKjjCRhm+laNvZSyNhkCD1oAfp+lXGpMFLkZPrXYjw8dNgiLNuJHT1qp4fhS2lWSSQYXsO9anjbWI4EtmhyWZcjmgCpIXt2BSMjvU8sllqVi8U6ETjox61yp8YMJP9KiO37ta1texXkSTQMp9R3NAGHd2iLIyuckcD6VUEotWygHHtW7rUCiLzkU88Ee9cvcOFJ3HmgCXUI4r0Cbfh8dKxpIpcneBiiW6C7lQkn27VTnu5yMZOKAEuoY9hPG6su4UDpUkkjnPJJ9KiIc9RQBWZTVeReDV/wAsk4xzUE8ZAOaAM2Qc1Ew4q1KhFQMOKAKcg4oqRx1ooAxaKKKACiiigBwY08NnAHaoxS0AadjqdzZsDFIQR2zWwnjDUkjKmYbT19a5UGjIoA17zWbq7OXlY/jVLzyxyxO6quacDxQBaEtLvqrml3CgCx5pFHnGq+4UbhQBY8403zKh3CjcKAJvMo8yoC1GaALQfinBj61UVqeW4oAs7z60mahD8UA80ASk1YtjVXNTwGgDTiarSHpVOKrkXUUAXYTWjZq7yiNelZkXWtnSWwHoA6nRp4bdChUM9W5rh5JODtHoK52E4IbcRWhFLuUD5ie1AGl9oZUxGSMeppviOS4vbW1lJz5Y28VTeYIMzYDe1JFfSOPJijMit1OOlAEtmkF1F5c8a9cE1d/4R64tx9p0uUlF5KUyzs2EyoVI5zXWaYtzbJwmU9KAOXvNXaXTmhlQrOp5yMVyi2tzcNuJPJr0/UobW9/1sGycfxY7VgXdj9nk4GVPf0oAyNI0uKNHMqhn7ZrM1CFlmcGLA+lbkxdThe1RSzGUbZlyPWgDkp1XkBQGqDyz6Gt27azhJYrkism6ufMOIRhaAKsmI8k9apTMJDmrTISeTk1E8ZxQBnSpzVdlrRkj5qBohuPFAGZKvBoqxcRgZwKKAOXooooAKKKKAClzSUUALSUUUAFKDSUUALmkoooAKKKKACiiigBQaM0lFAC55p240yigCYGnA1CDTwaAJs1Yh6VVWrUPSgDSt23dqvxCs+0rQi70AWozitDT5guTnrWcnarcYAHFAGsl+IxhUDfWg39zIRsYIPQDNZ8YFalnGpXOORQBLbKzuC7En0Ndf4d2BxhQSTjBFY2k20UkhZxk1uRnylIjAXntQBr60EsIVlYAu3Q+lcleeJL2O4CQy/KOtbPimaT+wVYtlsdTXn+nkyMS5yc0Adpa+KiwEeoxbCxwHHPFbQkgubVhDIHXGQ1Yum2kFzb7Zo1YAVQ3NYXZS2ZlUnGCc0AOv7iOCRlZuaxbu+LZVDx606/Yy3DFzk1DHEpC5HU4NAFAgzZxucd+KY8eByhr0ptMtIdHieOFQzDk1jXVvF/cFAHGCI44BxTHibHAya6OaCMMcLiqjxqM4FAGE1szdqRrYKvPJrXcAGoXUHJNAGJdW26MketFaMwAGMcUUAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Enlarged adenoid (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marilene B Wang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_26_26031=[""].join("\n");
var outline_f25_26_26031=null;
